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Louis R. Ghanem, PhD 
 
University of Pittsburgh, 2005 
 
 
Elevated levels of the molecular adaptor protein p21waf1/cip1 (p21) and of the IL-3 receptor α 
chain are correlated with chemoresistance and poor prognosis in acute myeloid leukemia (AML).  
p21 is a core regulator of many biological functions including cell cycle control, apoptosis and 
differentiation.  Our laboratory has demonstrated a decrease in p21 expression levels during 
cytokine-induced granulocytic differentiation, leading us to hypothesize that p21 antagonizes 
granulopoiesis.  The proliferative cytokine IL-3 has been shown to prevent granulocytic 
differentiation of murine and human myeloid progenitor cells.  We also hypothesized that IL-3 
inhibition of differentiation is mediated in part by p21, and tested this in murine 32Dcl3 
myeloblasts that are used to model granulopoiesis.  Our findings demonstrated that p21 
antagonized differentiation by promoting apoptosis of cells exposed to the differentiation inducer 
G-CSF.  We also showed that p21 prevented premature expression of primary granule proteins 
and contributed to maintenance of the myeloblast phenotype.  Furthermore, p21 knockdown 
accelerated morphologic differentiation of 32Dcl3 cells stimulated to differentiate with G-CSF.  
We then determined how IL-3 maintains p21 expression in myeloblast cells.  We showed that IL-
3 stabilized p21 mRNA in myeloblasts leading to high levels of p21 protein.  This effect mapped 
to the 3' untranslated region (UTR) of the p21 transcript.  p21 transcript stabilization by IL-3 was 
independent of PI3-kinase and ERK pathway signaling.  In vitro binding assays provided 
evidence that distinct sets of RNA:protein interactions occur within the proximal 303 nucleotides 
of the p21 3' UTR and are regulated by IL-3 and G-CSF signaling.  Association of a 60-65 kDa 
 iv
 protein with p21 riboprobes correlated with IL-3 mediated p21 mRNA stabilization, whereas 
binding by a 40-42 kDa protein was associated with destabilization of p21 transcripts in 32Dcl3 
cells undergoing G-CSF-induced differentiation.  These findings provide the first evidence for 
IL-3-mediated stabilization of mRNA transcripts in myeloid progenitor cells.  The finding that 
p21 antagonized granulopoiesis is also novel.  Because high levels of the IL-3 receptor and high 
p21 expression have separately been linked to poor outcomes in AML, IL-3 mediated p21 
mRNA stabilization may contribute to differentiation blockade during AML pathogenesis. 
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1. Introduction 
 
1.1. Overview 
Acute myelogenous leukemia (AML) results from uncontrolled cell growth of immature 
myeloid progenitor cells and accounts for 34% of all leukemias and 30% of all hematological 
malignancies1,2.  Despite advances in cancer therapeutics, the overall five-year survival of 
patients with AML remains at 14%.  Elevated levels of the molecular adaptor protein p21cip1/waf1 
(p21) are correlated with chemoresistance and poor prognosis in AML3.  p21 is a core regulator 
of many biological functions including cell cycle control, apoptosis and differentiation.  Control 
of p21 expression and function is complex, being regulated by cellular stress, growth factors, and 
differentiation stimuli; however, how p21 is regulated in hematopoiesis is not well understood.  
Our laboratory has demonstrated that p21 undergoes dynamic changes in expression levels and 
subcellular compartmentalization during cytokine-induced myeloid differentiation, suggesting 
that p21 may play an important role in myeloid development.  The mechanisms that control 
changes in p21 abundance and the resultant functional outcomes upon myelopoiesis have not 
been addressed and are the focus of this dissertation. 
Studies of monocytic cell lines have provided evidence to support an anti-apoptotic role 
for p21 in myeloid cells.  However, both the inhibition and promotion of apoptosis are functions 
that have been attributed to p21.  During granulocytic differentiation of human CD34+ cells, p21 
protein levels initially rise and then decline when blasts commit to terminal differentiation, a 
stage associated with decreased cell survival.  These findings led us to hypothesize that p21 
inhibits cell death during granulopoiesis, and that p21 downmodulation contributes to the 
1 
 differentiation-associated decrease in survival as granulocytes mature.  This hypothesis is 
explored in Chapter II using 32Dcl3 cells.  32Dcl3 cells are normal, diploid, myeloid progenitor 
cells of murine origin with high basal levels of p21 expression that depend upon IL-3 for 
survival, proliferation, and maintenance of an undifferentiated state4,5.  These cells provide a 
good model to study the effects of p21 upon myelopoiesis because they undergo granulocytic 
differentiation in response to G-CSF and recapitulate the dynamic changes in p21 expression 
observed during granulocytic differentiation of CD34+ human hematopoietic progenitor cells.  
Data within this chapter demonstrates that artificial maintenance of p21 levels leads to an 
unexpected proapoptotic activity during the myeloblast to granulocyte transition, suggesting the 
downmodulation of p21 that occurs in differentiating 32Dcl3 cells is necessary for survival. 
Experiments presented in Chapter III address why p21 levels decrease when IL-3 is 
replaced by G-CSF in the 32Dcl3 model system.  Because post-translational modification of p21 
protein can regulate its stability, it was hypothesized that IL-3 maintains p21 protein levels 
through inhibition of signal pathways linked with proteasomal decay of p21.  Our data did not 
support this hypothesis.  In contrast, our studies indicated that IL-3 acts posttranscriptionally at 
the level of p21 message.  IL-3 stabilizes p21 transcripts through control of protein:RNA 
interactions within the p21 3’ untranslated region.  These findings provide the first evidence for 
IL-3-mediated stabilization of mRNA transcripts in myeloid progenitor cells.   
Because IL-3 supports myeloid progenitor cell development in vivo and is an antagonist 
of terminal differentiation in 32Dcl3 cells, Chapter IV explores the hypothesis that IL-3 
suppresses granulocytic differentiation, in part, through maintenance of high p21 levels.  In 
support of an inhibitory role for p21 during differentiation, studies in primary keratinocyte 
precursors have demonstrated that p21 inhibits the expression of genes normally found in 
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 terminally differentiated keratinocytes and prevents their morphologic maturation.  Our 
investigations in differentiating myeloid cells revealed that siRNA-mediated knockdown of p21 
accelerated the kinetics of G-CSF induced differentiation. This was associated with premature 
expression of primary granule proteins.  The mechanism of this effect was at the 
posttranscriptional level.  Since high levels of p21 have been described in subsets of AML, our 
finding of accelerated differentiation in p21 knockdown cells suggests that differentiation 
blockade by p21 may be one mechanism that contributes to AML pathogenesis. 
Current literature regarding p21 structure and function is summarized in the Introduction 
in order to aid in the understanding of the experimental and interpretive framework used in our 
studies.  All experiments were conducted in myeloid cells, so a brief review of myelopoiesis with 
an emphasis on granulocytic maturation is presented first.   The extensive functional versatility 
of p21 warrants discussion of the role of p21 in cell cycle control and regulation of DNA 
synthesis, of how p21 contributes to apoptotic pathways, and the role of p21 in differentiation.  
Furthermore, it has become evident that a complex interplay of transcriptional, post-
transcriptional and post-translational mechanisms regulate p21 expression.  Background 
information on these mechanisms is therefore included.   Lastly, a review of IL-3 biology as it 
pertains to myeloid development and AML pathogenesis will be discussed. 
 
1.2. Myelopoiesis 
Myelopoiesis is the process whereby myeloid cells, monocytes and granulocytes, develop 
from pluripotent hematopoietic stem cells (HSCs) in the bone marrow.  Myeloid cells are critical 
mediators of antimicrobial and inflammatory responses.  Their production results from a linear 
progression where HSCs become committed myeloid progenitors (CFU-GEMM), capable of 
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 producing all myeloid blood elements (i.e., granulocytes, erythrocytes, macrophages and 
megakaryocytes), then form lineage-specific precursors restricted to production of monocytes 
and granulocytes (CFU-GM).  Final maturation into granulocytes (i.e., neutrophils) or monocytes 
is influenced by specific cytokines and the sequential activation of lineage-specific transcription 
factors.  Monocytic differentiation from CFU-GM precursors is dependent upon the cytokine M-
CSF and PU.1/c-jun transcriptional activity6-8.  Whereas IL-3 is important for the development of 
the common myeloid progenitor, (reviewed in section 1.6), the cytokine G-CSF is an important 
mediator of neutrophil maturation9.  Indeed, mutations in the G-CSF receptor are responsible for 
a variety of clinical conditions characterized by insufficient neutrophil production10.  Transition 
from myeloblasts, the first morphologically identifiable granulocytic precursor, to terminally 
differentiated neutrophils requires the activation of the transcription factor CCAAT/enhancer 
binding protein α, C/EBPα6,11.  Expression of neutrophil granule proteins, enzymes responsible 
for neutrophil killing functions, also occurs during this transition and is mediated in part by the 
related transcription factor C/EBPε12.  Mutations which impair C/EBPα transcriptional activity 
cause developmental arrest at the myeloblast stage and are responsible for the development of 
AML in some patient populations13,14.  Failure to complete the myeloid differentiation program 
is a central etiologic factor in myeloproliferative syndromes and myeloid leukemia pathology. 
 
1.2.1. Acute Myelogenous Leukemia 
 Acute myelogenous leukemia (AML) is a hematologic malignancy characterized by rapid 
proliferation of abnormal blast cells and impairment of normal blood cell production.  AML 
constitutes the majority of all leukemias and is responsible for 1.2% of all cancer deaths in the 
United States15.  Although AML can afflict both adults and children, it is predominantly a 
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 disease of adulthood with a rising incidence in each decade after the age of 50.  Therapies have 
improved overall 5-year survival rates to near 50% for all leukemias, however, five-year survival 
for patients with AML is under 20% and has not improved significantly over the past decade2.  
Combination chemotherapeutic regimens are used as first-line therapy to induce remission.  
Complications of this therapy include bone marrow suppression, which by itself is sometimes 
fatal, and the production of drug resistant leukemic blasts when therapy is unsuccessful. 
Failure to complete the normal myeloid differentiation program at different stages is 
implicated as contributing to AML because of the heterogeneity of undifferentiated blasts found 
in subtypes of the disease.  When this happens, accumulation of abnormal blasts in the bone 
marrow occurs, and serves to impair the synthesis of normal leukocytes, red cells, and platelets.  
The clinical manifestations of the disease stem mainly from this loss of production.  Left 
untreated the course of the disease is rapid, leading to death within six to twelve months16. 
AML molecular pathogenesis is characterized by cytogenetic abnormalities as well as 
intragenic mutations.  Morphologic subtypes of AML are often correlated with specific 
chromosomal translocations which create leukemogenic fusion proteins such as the AML-ETO 
fusion protein (t(8;21), M2 subtype)17.  Activating mutations in receptor tyrosine kinases such as 
Flt3 or c-Kit, or activating mutations in the small GTPase Ras are also prevalent in AML18-20.  
Hematopoietic transcription factors such as C/EBPα and GATA-1 are subject to inactivating 
point mutations in many cases13,21.  Often, the molecular defect underlying the cause of AML is 
not identified.  Despite this, high levels of a growing number of genes are being correlated with 
disease severity and prognosis, including the IL-3 receptor α chain and p21, and therefore 
warrant further investigation3,22.   
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 1.3. p21 Structure 
The human p21 gene is located on chromosome 6, maps to the p arm at 21.2 (6p21.2) and 
spans 8.6 kilobases.  p21 has two characterized splice variants which both encode an identical 
protein of 164 amino acids (Genbank Accession # NM_078467, and NM_000389).  These 
variants differ in length by 141 nucleotides in the 5’ untranslated region, however, the functional 
significance of this difference remains to be identified.  p21 function has undergone extensive 
study in murine systems.  The homologous murine p21 gene spans 6.9 kilobases, is located on 
chromosome 17 at 15.23 cM (Genbank Accession # NM_007669) and produces a 159 amino 
acid protein.  The nucleotide and protein sequences contain 76% and 79% similarity, 
respectively, with the human homologue. 
The human p21 protein is an adapter molecule with no known catalytic function.  It is 
grouped together by sequence homology with two other proteins, p27 and p57, into the Cip/Kip 
family of cyclin-dependent kinase inhibitors (CDKIs).  Most p21 functions have been ascribed to 
either its N-terminal or C-terminal domains.  The CDK (AA 49-71) and Cyclin (AA 21-26) 
binding domains of p21 reside in its N-terminal region and are conserved among the Cip/Kip 
family members.  Sequence homology diverges at the C-terminus with that of p21 being 
promiscuous in its binding affinities.  A secondary Cyclin-binding domain is found in the C-
terminus (AA 153-159), which overlaps p21’s nuclear localization sequence (AA 140-159) and 
its PCNA binding domain (AA-141-160).  Structure-function and protein interaction mapping of 
p21 domains has been largely ascertained through mutational analysis.  Although crystal 
structure data is available for small C-terminal polypeptides (<20 amino acids), atomic resolution 
of the full-length p21 protein has not been achieved. 
Despite the lack of crystallographic data, elements of p21 tertiary structure have been 
inferred from analysis of crystal structures of the homologous kinase inhibitory domains of p27 
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 in complex with Cyclin A and Cdk223.  p27 was shown to bind both Cyclin A and Cdk2 through 
its Cyclin and CDK binding domains respectively.  Stabilization of these two domains occurs 
through formation of an α-helix by the intervening residues.  Although sequence homology 
within the Cip/Kip family for this linker region is minimal, secondary structure prediction and 
circular dichroism analysis suggest an α-helical structure is present in all three proteins, and 
corresponds to amino acids 27-48 of p2124,25.  Inhibition of the Cyclin A/Cdk2 complex was 
postulated to occur through two mechanisms.  First, p27 binding was shown to alter the shape of 
the Cdk2 catalytic cleft; and second, a p27 helix caused a steric blockade of the ATP binding 
site.  Understanding of p21 secondary and tertiary structure is further limited because p21 is 
intrinsically unstable in solution, failing to maintain a defined conformation24.  This observation, 
coupled with spectroscopic examination of p27, prompted Lacy et. al. to hypothesize that the 
specificity of p21 interactions are governed by a folding-on-binding mechanism25,26.  This 
hypothesis proposes that intrinsically disordered molecules such as p21 and p27 obtain a more 
ordered confirmation only after initial contact with a binding partner.  It was further proposed 
that the specificity of interactions within multiple protein complexes is mediated by the first 
binding partner; and in the case of p27 or p21, initial binding to a particular Cyclin determines 
which conformation is adopted and therefore controls which other interactions will take place. 
1.4. p21 Biological Functions 
First identified in 1993 as a regulator of cell cycle progression, p21 is now known as a 
molecular adaptor protein with pleiotropic effects.  p21 lacks an identified enzymatic activity and 
therefore functions through its association with an ever growing cohort of binding partners.  
Through these interactions, p21 exerts its influence on distinct cellular functions such as DNA 
replication, transcriptional control, apoptosis, differentiation and cell migration.  p21 behavior is 
7 
 complicated by observations that demonstrate p21 to have opposing functions that are tissue-type 
dependent or dependent upon its nuclear or cytoplasmic localization.  For example, p21 can be 
both pro- and anti-apoptotic, can both promote and inhibit differentiation and transcription, and 
is associated with both active and inactive enzyme complexes (Fig. 1).  The in vivo consequences 
of many p21 protein interactions remain to be identified, leaving open the possibility that p21 
functions in other cellular processes. 
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Figure 1.  p21 Biological Functions. 
p21 regulates multiple cellular processes.  p21 both promotes and inhibits cell cycling through 
interactions with distinct Cyclin-Cdk complexes and can block DNA synthesis through inhibition 
of PCNA, a component of the DNA polymerase holoenzyme.  p21 regulates the function of both 
enzymatic and non-enzymatic proteins to influence apoptotic and transcriptional processes, as 
well as cell motility.  Although the mechanisms are ill-defined, p21 either promotes or inhibits 
differentiation in several tissue types.  The diversity of specific intracellular protein interactions 
are highlighted. 
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1.4.1. Regulation of the Cell Cycle and DNA synthesis 
Proliferating cells traverse through several phases before dividing.  These phases are 
grouped in what is known as the cell division cycle, or cell cycle.  The cell cycle is divided into 
two growth phases, G1 and G2, a DNA replication phase, known as the S phase, and mitosis.  
Cell cycle progression proceeds from G1 to the S phase, is followed by G2 and culminates with 
mitosis.  Phase transitions are known as checkpoints and transition from one phase to another is 
dependent upon the activity of cyclin and cyclin-dependent kinase (CDK) complexes.  Control of 
cyclin-CDK complexes is multifactorial, and includes negative regulation by cyclin-dependent 
kinase inhibitors (CDKI) which are comprised of two protein families, the INK4a (p15, p16, p18, 
p19) and the Cip/Kip (p21, p27, p57).   INK4 proteins bind to Cdk4 and Cdk6 complexes, 
thereby liberating Cip/Kip proteins sequestered by these CDKs; this frees Cip/Kip proteins to 
block cycling by binding to nuclear Cdk2 complexes.  Cip/Kip family proteins  inhibit cyclin-
CDK complexes through binding of both the cyclin and CDK proteins, and are not restricted to 
G1 regulation (for review, 27).  p21 was the first identified CDKI.    
Early work on p21 described it as the downstream effector of p53-induced growth arrest 
(i.e. Wild-type p53 Activated Fragment or WAF1) 28.  An independent and simultaneous study 
identified p21 as a Cdk-interacting protein (p21Cip1), causing arrest through direct interaction and 
inhibition of Cdk2 kinase activity 29.  Growth arrest following DNA damage and other cellular 
stressors occurred at the G1-to-S transition of the cell cycle30, but it was later shown that p21 
could also arrest cells in the G2 phase31, and prevent G2 arrested cells from re-entering S phase 
following DNA damage32.  In other early studies, Zhang et. al. identified p21 as a component of 
quaternary complexes in association with cyclins, CDKs and the proliferating cell nuclear 
10 
 antigen (PCNA)33.  PCNA is a subunit of DNA polymerase δ and is necessary for processivity of 
this enzyme.  Through its interaction with PCNA, p21 was shown to be a potent inhibitor of 
DNA synthesis following DNA damage, doing so without inhibiting PCNA-dependent 
nucleotide excision repair 34,35.   
p21 can bind to several different combinations of Cyclin and CDK complexes to control 
their activity.  p21 is most efficient as an inhibitor of Cdk/Cyclin-A or Cdk/Cyclin-E complexes 
to cause cell-cycle arrest36,37.  Conversely, p21 promotes assembly of Cdk/Cyclin-D complexes 
and remains associated with active complexes during G1 phase in proliferating cells 38-40.  A 
prevailing model suggests that the pool of available, or unbound, p21 is regulated through 
association with Cyclin/CDK complexes27.  The model predicts that sequestration of free p21 
into active Cdk/Cyclin-D complexes prevents its inactivation of Cdk2/Cyclin-E or -A complexes, 
enabling the unfettered progression of the cell cycle, and suggesting that p21 can serve as an 
assembly factor for Cyclin:Cdk complexes to drive proliferation27. 
S phase DNA replication is dependent upon expression of many genes that are controlled 
by the Rb (pRB, p107, p130) and E2F (E2F1 – E2F7) family of transcription factors.  E2F 
proteins activate transcription of S phase genes and are targeted by negative regulators of the cell 
cycle.  Hypophosphorylated Rb proteins act as transcriptional repressors and contribute to the 
maintenance of G1 cell cycle arrest.  Rb repressor functions are executed through formation of a 
repressor complex with E2F proteins, as well as recruitment of histone deacetylases to E2F 
containing promoters41,42.    Active Cdk4/6- and Cdk2-cyclin complexes phosphorylate Rb 
family proteins downstream of mitogenic signals.  Hyperphosphorylation of Rb triggers the 
release and derepression of E2F proteins, allowing for E2F transactivation (for review, 43.  p21 
regulation of this pathway is threefold.  First, direct interaction and inhibition of Cdk2/Cyclin 
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 complexes promotes the accumulation of hypophosphorylated Rb and repression of E2F29.  
Second, p21 can disrupt existing interactions between Cdk2 and p130-E2F complexes44.  Last, 
accumulating evidence indicates that p21 can associate with promoter elements, bind E2F 
subunits directly and inhibit their transcriptional activity independent of Cdk2 modulation 45,46.    
Although this analysis presents a simplification of the Rb-E2F transcriptional regulatory axis, it 
serves to illustrate that p21 control of the G1-S transition is accomplished through multiple 
mechanisms, acting as both an allosteric and competitive inhibitor, as well as a transcriptional 
repressor. 
Induced expression of p21 was found to decrease the expression of genes associated with 
DNA synthesis and cell proliferation, and also increase the expression of genes associated with 
senescence47.  Several studies have shown p21 to interact with and inhibit transcription factors 
which are key effectors of mitogenic signaling pathways such as Stat3, c-Myc and E2F as noted.  
Repression of Stat3 transcriptional activity was found to occur through direct interaction by p21 
and did not require disruption of Stat3 DNA binding ability48.  Although the p21 domain 
responsible for inhibition was not identified in this study, the C-terminal PCNA binding domain 
of p21 was found to act as a transcriptional repressor of c-Myc, preventing association of the c-
Myc:Max heterodimer with E-box elements49.  It is interesting to note that Kitaura et. al. also 
observed that titration of c-Myc was able to rescue DNA synthesis blocked by p21 repression of 
PCNA.  This may represent a possible reciprocal regulatory circuit between p21 and c-Myc that 
is governed by the relative abundance of each molecule.  It is likely that repression of mitogenic 
transcription factors and inhibition of DNA synthesis through PCNA repression are two 
complementary mechanisms used by p21 to exert S phase control.  These mechanisms may also 
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 support ongoing blockade of DNA synthesis and cell cycle progression that accompany p21 
induced cellular senescence. 
One early study utilizing a cDNA library expression screen determined that p21 
expression was sufficient to block cell proliferation and induce a senescent phenotype50.  Gene 
knockout studies revealed that the absence of p21 was sufficient to prevent senescence in 
fibroblasts51, whereas in keratinocytes this phenotype depended upon  ablation of both p21 and 
p14(ARF)52.  Recent work has demonstrated that translational control of p21 by the RNA 
binding proteins CUGBP1 and Calreticulin contributes to the determination of cell fate in 
fibroblasts53.  CUGBP1 was found to relieve translational repression by Calreticulin through 
competition for an element in the p21 5’UTR, causing an increase in p21 protein expression, 
growth arrest and a senescence phenotype.  Furthermore, induction of senescence by p21 has 
been shown to correlate with radiation and chemoresistance54.  Data support a role for p21 as an 
inducer of senescence, however, the mechanism of this function remains unclear.  In addition to 
negative regulation of the cell cycle, data support an anti-apoptotic function of p21 during 
replicative senescence. 
 
1.4.2. Regulation of Apoptosis and Stress Responses 
p21 has been found to regulate apoptosis in response to many different stimuli including 
oxidative stress, chemotherapeutic agents, radiation, and death receptor activation.  Both the 
inhibition and promotion of apoptosis by p21 has been described.  The preponderance of 
literature defines p21 as an apoptotic inhibitor and the majority of the following discussion will 
address this function.  Numerous studies of human cancers have linked high levels of p21 
expression to chemoresistance and poor prognosis 3,55.  While only a few mechanisms have been 
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 delineated, the effect of p21 on apoptosis is often dependent upon two factors, its abundance and 
its intracellular localization.  The role of p21 in apoptosis is further characterized by its control 
of both p53-dependent and p53-independent apoptotic processes. 
Evidence suggests that p21 protects cells from p53-induced apoptosis while mediating p53-
dependent cell cycle arrest56.  p53 tumor suppressor activity is essential for maintenance and 
repair of the genome, and promotes apoptosis or growth arrest following genomic insults.  The 
mechanism of p53-induced apoptosis is not well understood, but results in part from 
transcriptional activation of genes controlling apoptosis that can activate mitochondrial and death 
receptor apoptosis pathways (for review57.  p21 may serve to switch cells from the p53 death 
pathway to a growth arrest phase during which DNA repair can occur58. 
Studies utilizing melanoma and colorectal carcinoma cell lines demonstrated that high 
levels of p53 expression could trigger apoptotic responses59,60.  Inactivation of p21 in colon 
carcinoma cell lines by homologous recombination was shown to increase the sensitivity of cells 
to p53-induced apoptosis59.  Furthermore, murine embryonic fibroblasts (MEFs) derived from 
p21 knockout mice (p21-/- ) underwent high levels of apoptosis in response to overexpression of 
p5360.  Ectopic expression of p21 in these MEFs, as well as in p53 sensitive melanoma cell lines, 
was found to protect against p53-induced apoptosis and enhance survival60.  c-Myc has been 
reported to prevent activation of p21 by p53 following DNA damage, thereby increasing p53-
directed cell death in damaged cells61.  Together these findings suggest that p21 expression 
levels are an important determinant of the balance between growth arrest and apoptosis 
stimulated by p53 activation. 
p21 can also oppose several p53-independent apoptotic pathways, such as those induced by 
cytokines or subclasses of chemotherapeutic agents that do not induce p53 expression.  High 
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 levels of p21 expression have been shown to inhibit TGF-β induced apoptosis in retinal 
endothelial cells62.  In a model of monocytic differentiation, NF-κB mediated upregulation of 
p21 was shown to prevent apoptosis that was induced by autocrine production of TNF-α 63.  In 
glioma cells, downregulation of p21 using antisense oligonucleotides caused an increase in 
sensitivity to CD95-ligand induced apoptotic signals.  In addition, STAT1-dependent p21 
expression has been shown to be protective in the setting of IFN-γ induced apoptosis64.  Gene 
knockout studies revealed that induction of p21 in bone marrow derived macrophages by IFN-γ 
treatment was required to protect against apoptotic stimuli such as growth factor withdrawal or 
treatment with lipopolysaccharide65.  p21 has also been shown to oppose apoptosis induced by 
microtubule inhibitors (MTIs).  p21 deficient cells were shown to experience more apoptosis 
following treatment with the MTIs Taxol and vincristine; and rescue of this phenotype was 
accomplished by ectopic expression of p2166.  The HER2/neu oncogene is overexpressed in 
many breast cancers, and its expression is correlated with increased resistance to chemotherapy 
with Taxol67.  It has been shown that HER2/neu-overexpressing cells induce resistance to Taxol 
through transcriptional activation of p2168.    
p21 may prevent apoptosis in part by antagonizing Cdk2.  Cdk2 activity has been shown to 
be a necessary component of the effector phase of apoptosis69-71.  These studies revealed that an 
increase in Cdk2/CyclinA nuclear localization and activity occurred as a result of caspase-3 
activation.  Partial blockade of apoptosis resulted from expression of either Cdk2 dominant 
negative mutants, pharmacologic inhibition of Cdk2, or, significantly, by expression of a caspase 
cleavage resistant mutant of p21. 
Caspase 3 has been reported to undermine antiapoptotic functions of p21 by cleaving p21.  
Caspase-3 mediated cleavage of p21 has been shown to occur following γ-irradiation, treatment 
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 with chemotherapy molecules, or oxidative stress72-74.  In each circumstance, p21 cleavage was 
correlated with an increase in Cdk2 activation and with increased apoptosis.  p21 cleavage 
occurs in the C-terminal region of the protein at D112, an aspartic acid that is part of the caspase 
recognition motif (DHVD112L)70.  Cleavage separates the CDK inhibitory domain (AA 49-71) 
from the nuclear localization sequence (AA 140-159).  Cytoplasmic localization of the residual 
N-terminal domain results as a consequence.  Compartmental separation of p21 and Cdk2 was 
correlated with an increase in Cdk2 activity, as well as an increase in apoptosis75.   
Conversely, in some cell types, cytoplasmic localization of the full length p21 protein 
exerts a protective effect against apoptosis.  This effect is mediated through direct interactions 
with several molecules thought to be involved with the initiation and effector steps of apoptosis.  
Interaction between p21 and procaspase-3 was found to inhibit Fas-mediated apoptosis and block 
caspase activation in human hepatoma cells 76,77.  p21 prevented procaspase-3 proteolysis 
through blockade of the p3 serine protease recognition site.  Furthermore, in a model of DR4 
TRAIL receptor inducted apoptosis, p21 overexpression in breast, lung and colon cancer cell 
lines was shown to block cleavage of the initiator caspase, caspase 878.  Our laboratory has 
shown in the leukemic cell line K562 that induced expression of p21 promoted the stabilization 
of the apoptotic inhibitor protein c-IAP1 and correlated with an increase in chemoresistance79.  
These findings support the hypothesis that cytoplasmic p21 opposes the activity of central 
components of the apoptotic cascade and that the survival promoting effects are not dependent 
upon p21 nuclear localization in all cell types. 
Signals initiated by cellular stressors such as TNF-α, radiation and oxidative stress are often 
transduced by cytoplasmic kinases resulting in growth arrest or engagement of the apoptotic 
machinery.  Shim et. al. found that p21 expression was sufficient to inhibit the activation of 
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 stress-activated protein kinase (SAPK or JNK), a terminal effector of stress pathway signaling 
whose activation can lead to apoptosis80.  Subsequently, Asada et. al. determined that p21 
mutants restricted to expression in the cytoplasm resulted in decreased SAPK activation and 
were able to inhibit apoptosis triggered by multiple stimuli81.  Moreover, they found that p21 
control of SAPK activity was a result of p21 binding and inhibition of the apoptotic-signal 
regulating kinase, ASK1, and that this regulation occurred within the cytoplasmic compartment.  
The molecular mechanism of p21 inhibition of these kinases remains unresolved, however, it is 
evident from these studies that p21 retains sufficient plasticity to interact with and inhibit 
multiple kinases, in addition to Cdk2, to enhance cell survival.   
In contrast with the above reports, several studies have linked p21 to the promotion of 
apoptosis.  These studies utilized either p21 overexpression or were conducted in systems that 
suppressed p21 expression.  In overexpression studies, p21 was sufficient to promote apoptosis 
or promoted apoptosis in conjunction with death receptor activation82,83, DNA damaging 
agents84,85, ionizing radiation86, or antioxidant treatments87-89.  Exogenous p21 alone has been 
sufficient to induce apoptosis in cervical90, esophageal91, and breast cancer cell lines92 and a 
peptide corresponding to the C-terminus of p21 has recently been shown to cause apoptosis in 
the U937 myelomonocytic cell line 93.  p21 suppression by gene deletion or antisense techniques 
attenuated apoptosis induced by death receptor activation in thymocytes83, retinoids in hepatoma 
cell lines94, and by expression of the DNA-repair protein RAD50 in colon carcinoma cells89.  It 
has been speculated that p21 may exert its proapoptotic effects through interactions with the 
DNA repair machinery56.  The proapoptotic effect induced by p21 C-terminal peptides was 
shown to require disruption of the outer mitochondrial membrane, but was independent of 
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 caspase activation, and suggests a mechanism that can be separated from p21 activity in the 
nucleus93.  
In summary, numerous reports support a role for p21 in apoptosis regulation, although few 
details are known regarding how p21 regulates apoptosis.  p21 antiapoptotic functions have been 
attributed to p21 compartmentalization either in the nucleus or cytoplasm.  Direct binding and 
inhibition of apoptotic effectors, stabilization of negative regulators, and inhibition of stress 
pathway kinases are mechanisms mediated by cytoplasmic p21.  As in the p53-dependent 
response to stress, where absolute levels of p21 expression are linked to cellular decisions to 
undergo either growth arrest or apoptosis, it is plausible that the ratio of cytoplasmic and nuclear 
p21 govern the apoptotic outcome.  The antiapoptotic effects of p21 have been correlated with 
chemoresistance in numerous studies and implicate p21 as an important contributor to cancer cell 
survival.  A proapoptotic function for p21 has also been characterized, but mechanisms remain 
speculative. 
 
1.4.3. Control of Differentiation 
Changes in p21 levels have been linked to differentiation in several cell types including 
muscle, neuronal, epidermal and hematopoietic cells.  Differentiation and cell proliferation are 
coordinated in a precise fashion during development.  Terminal differentiation is associated with 
growth arrest which is mediated by upregulation of one or several cell cycle regulatory proteins, 
particularly cyclin-dependent kinase inhibitor family members, including p21.  This raised the 
speculation that p21 was responsible for exit of terminally differentiating cells from the cell 
cycle95.  In differentiating myotubes, MyoD induction of p21 appeared to support this view96.  
However, high steady-state levels of CDKI’s are found in both mitotic myeloid and erythroid 
18 
 progenitors as well as in post-mitotic differentiated cells, suggesting that in these lineages 
CDKI’s do not simply couple differentiation to growth arrest 95,97-100. 
p21 has been shown to promote cellular differentiation in several tissues.  p21 
overexpression can promote differentiation of myelomonocytic, promyelocytic and erythroid 
leukemia cell lines101-103.  In muscle, p21 expression can be directly activated by MyoD, a 
muscle-specific, differentiation-promoting transcription factor104,105.  Furthermore, under 
conditions of differentiation suppression, exogenous expression of both p21 and p16ink4a in 
myoblasts was sufficient to induce muscle-specific genes and cell cycle withdrawal106.  In a 
study of xenopus retinal progenitors, Ohnuma et. al. showed that p21 expression was sufficient 
to induce glial cell differenatiaion107. Analysis of oligodendrocytes from p21-/- mice 
demonstrated that differentiation required p21108. 
On the other hand, there is some support for an inhibitory role for p21 during 
differentiation.  Our laboratory has shown that p21 expression is dramatically decreased in post-
mitotic granulocytes in both normal cell lines and cord blood derived stem cells differentiated in 
vitro100.  This supports the finding of high p21 levels in undifferentiated myeloblasts isolated 
from patients with chemoresistant AML3.  Additionally, in primary keratinocyte precursors, p21 
inhibits the expression of genes normally found in terminally differentiated cells and prevents 
morphologic maturation109. 
The differentiation effects of p21 have been shown to be independent of its cell cycle 
modulating ability in several of these systems.  p21 can promote differentiation in promyelocytic 
leukemia cells without inhibiting cell-cycle progression103.  In oligodendrocytes and retinal 
progenitors, neural differentiation stimulated by p21 was shown to be independent of its ability 
to regulate CDKs or cause growth arrest107,108. In keratinocyte progenitors, p21-induced 
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 differentiation blockade was a function localized to the p21 C-terminal domain109.  Deletion of 
the C-terminus abrogated the inhibitory effect, suggesting that inhibition was independent of 
CDK binding and control. 
However, CDKI’s are necessary to maintain cell cycle arrest in terminally differentiated 
cells.  The timing of CDK inhibition is increasingly thought to be an important factor in 
proliferative and survival signaling during differentiation98.  Using murine erythroleukemia cells 
in a model of erythropoiesis, Matushansky et. al. revealed that a specific order of CDK inhibition 
was required to commit proerythroblasts to differentiate102,110.  Transition to the differentiated 
state required first the inhibition of Cdk2, followed by inhibition of Cdk6.  They showed that 
either expression of p21 or the combined use of roscovitine, a Cdk2 inhibitor, followed by 
overexpression of p16, a Cdk4/6 inhibitor, could induce differentiation110.  Reversing the order 
of inhibition did not result in differentiation, but caused cell death instead110.  For p21 induced 
differentiation, they reasoned that p21 can directly inhibit Cdk2, but mediates indirect inhibition 
of Cdk6.  p21 can promote dissociation of p16 from cytoplasmic Cdk4 complexes, thus making 
it available to inhibit Cdk6110.  Growth arrest was correlated with late stage upregulation of p27, 
which is also seen in myeloid differentiation, and a late drop in Cdk4 activity110.  It is 
conceivable that an analogous system of precise temporal inhibition of Cdk’s is also controlled 
by p21 in epidermal, neural and muscle tissues.  
 The role of p21 in differentiation has also been characterized using mice carrying 
homozygous deletions of the p21 gene.  Initial p21 knockout animals (p21-/-) displayed no gross 
developmental abnormalities, suggesting that p21 is not a necessary component in differentiation 
pathways30.  By contrast, p21 and p57 double null animals had severe defects in lung alveoli and 
skeletal muscle111.  This implicates a functional redundancy of these proteins during 
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 development, and illustrates the difficulty of interpreting findings from single gene knockout 
studies.  However, closer scrutiny of cells derived from p21-/- single knockout animals initially 
revealed defects in both hematopoietic and epidermal stem cell development.  In p21-/- 
hematopoietic stem cells, Cheng et. al. demonstrated that p21 inhibits stem cell cycling and helps 
to regulate stem cell population size by controlling the balance of self-renewal versus 
proliferation112.  Absence of p21 in keratinocyte stem cells allows self-renewal to go unchecked 
and results in a similar expansion of the stem cell compartment 113.  These knockout studies link 
p21 to control of stem cell proliferation and normal differentiation in multiple tissues. 
Data from knockout studies has also shown that p21 may have a tumor suppressor function.  
Long term study of p21 deficient mice (~2 years) revealed an increased susceptibility to 
hematopoietic, endothelial and epidermal tumors114.  Ras-transformation of p21-/- primary 
keratinocytes also was shown to be sufficient to promote tumor formation in mice when 
compared to controls containing wild-type p21115.  Subsequent animal studies demonstrated that 
p21-/- keratinocytes were more susceptible to carcinogenesis induced by DMBA and displayed a 
greater prevalence of higher grade undifferentiated skin tumors 113,116,117.  These studies 
implicate inactivation or suppression of p21 as a mechanism that contributes to malignancy in 
multiple tissues. 
Knockout models have indicated two functions of p21 in differentiating muscle and 
neuronal cells.  One function is to oppose differentiation-associated apoptosis.  p21-/- myogenic 
progenitors were found to have defects in skeletal muscle regeneration following injury, with 
increased levels of apoptosis during differentiation 118.  In support of this function, forced 
expression of p21 alone was sufficient to inhibit differentiation-induced apoptosis in cell line 
models of myogenesis119.  In neuroblastoma cells, antisense suppression of p21 revealed that p21 
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 was antiapoptotic during differentiation120.  Because p21 antiapoptotic effects have not been 
linked to differentiation in other tissues, these studies suggest that the role of p21 in cell survival 
during differentiation is tissue-specific and therefore not generalizable. 
A second function of p21 derived from knockout studies is the promotion of cytoskeletal 
reorganization in neural cells.  One early finding demonstrated that a delay in cerebellar 
myelination occurs in p21-/- mice108.  Myelination requires the cytoplasm of glial cells (Schwann 
cells) to form processes that ensheath neural axons in response to axonal signals that have yet to 
be identified121.  Cytoplasmic p21 has been found to regulate neurite remodeling during 
differentiation of retinal progenitors through association with and inhibition of Rho kinase 
(ROCK) 81,122.  Interestingly, cytoplasm restricted p21 mutants were found to stimulate axonal 
regeneration following spinal cord injury by promoting myelination of neuronal outgrowths, a 
process inhibited by active ROCK in this setting123.  One can hypothesize from these findings 
that p21 is a node that integrates axonal myelination signals.  In this capacity p21 may promote 
the formation of cytoplasmic outgrowths from axons that interact with and stimulate myelin 
production from surrounding myelin producing cells. 
1.5. Regulation of p21 
1.5.1. Gene Expression 
Expression of the p21 gene is controlled through transcriptional activation and repression, 
and, to a much lesser extent, epigenetic silencing.  Transcriptional activation of p21 was first 
described to be regulated by p53 in 199328.  In 1994, our laboratory determined that p21 
undergoes p53-independent transactivation in the setting of myeloid differentiation95.  Since 
then, many transcription factors that regulate p21 gene expression have been identified including 
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 Sp1/Sp3, vitamin D receptor (VDR), retinoic acid receptor (RAR), AP2, Miz-1, STAT family 
proteins (STAT1/3/5), C/EBPα, C/EBPβ, E2F1/3 and c-Myc (for review, 124). 
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Figure 2.  Transcriptional regulation of the p21 gene promoter.  
An extensive array of response elements in the p21 promoter (filled ovals) are bound by 
transcriptional regulatory proteins downstream of an equally diverse set of extracellular stimuli 
resulting in p21 transcriptional activation.  Transcriptional repression of p21 occurs through 
direct binding of the promoter (e.g., Gfi-1b) or through inhibition of transactivating factors.        
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 There are two p53 binding elements in the human p21 promoter approximately 1.4 and 2.3 
kilobases upstream of the transcriptional start site (1.9 and 2.8 Kb in mice) that are conserved in 
humans, rats and mice (Fig. 2).  p53 binding to one of these elements is sufficient, but not 
required for p21 activation125.  The promoter-proximal element is also bound by a repressor 
protein distinct from p53 in CD34+ progenitor cells; this protein disengages during 
myelopoiesis100.  Additional evidence of p53-independence comes from p53 knockout mice (p53-
/-), where p21 expression is found in multiple embryonic and adult tissues126.  The p53-dependent 
pathway of p21 activation is also subject to negative regulation by a variety of mechanisms.  p53 
can be bound and inactivated by phosphorylation127, bound and targeted for destruction by viral 
proteins128, or, alternatively, blocked from binding the p21 promoter by competition129.  
Although recent identification of a tumor suppressor function of p21 has been made in 
prospective studies of p21-/- mice114, an extensive study of the p21 gene in human malignancies 
by single-strand conformation polymorphism analysis determined that intragenic mutations of 
p21 were rare130.  However, there is evidence that p21 inactivation occurs as a result of p21 
promoter hypermethylation within STAT1 and Sp1/Sp3 response elements 131,132.  Despite some 
conflicting reports, broader studies of p21 promoter methylation in both solid and humoral 
human malignancies indicate that p21 gene silencing secondary to hypermethylation is a rare 
event133-136.  Epigentic silencing or coding region mutations do not seem to be implicated as 
mechanisms of p21 inactivation in human cancers.  It remains to be determined if methylation of 
p21 DNA sequences contributes to p21 regulation during normal development or ongoing 
cellular activities in differentiated tissues. 
Numerous differentiation signal pathways, activated independent of the p53 stress response, 
can also induce p21 transcription.  In the myelomonocytic leukemia cell line U937, the 
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 differentiation inducing agents phorbol ester (12-O-tetradecanoyl phorbol-13-acetate, TPA) and 
okadaic acid were shown to induce p21 transcription via GC-rich Sp1 binding sites in the p21 
proximal promoter137.  These agents also induce p21 transcription through activation of the AP2 
transcription factor in K562 leukemia cells, suggesting that alternative pathways exist in 
leukemia subtypes that can activate p21 transcription 138.  Nerve growth factor (NGF) triggers 
neuronal differentiation in PC12 cells.  In these cells, NGF stimulates the transcriptional 
coactivator p300/CBP, a histone acetylase, to associate with Sp1 and Sp3 at the p21 promoter, 
causing a cooperative induction of p21 transcription139,140.  Although the p21 gene elements 
responsible for its function are unknown, MyoD, a muscle specific transcription factor that 
induces myogenesis, also activates p21 transcription in cooperation with p300/CBP96,141. 
In adipocytes and hepatocytes, expression of the transcription factor C/EBPα increases 
during differentiation and is highest in terminally differentiated, growth arrested cells 142,143.  A 
concomitant increase in CDKI expression, particularly p21, is also observed in these cell 
types144,145.  C/EBPα can activate the p21 promoter and also stabilizes p21 protein expression 
through direct interaction144,146.  Furthermore, cell cycle arrest stimulated by glucocorticoid 
receptor signaling in hepatoma cell lines was found to be dependent upon a consensus C/EBPα 
binding element in the p21 promoter147. 
Keratinocyte differentiation induced by calcium is mediated by calcineurin, a calcium 
dependent phosphatase, and is associated with upregulation of p21 transcription148,149.  p21 
promoter activation by calcineurin is dependent upon Sp1/Sp3 binding and may be synergized 
through association of NFAT1/2 transcription factors (nuclear factor of activated T cells).  
Activation of Notch signaling pathways also coordinate keratinocyte growth and differentiation.  
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 Rangarajan et. al. identified RBP-Jκ as a protein that binds the endogenous p21 promoter and 
activates p21 expression in response to Notch1 signals150. 
p21 activation also occurs as a result of cytokine and lipid hormone induced differentiation 
in hematopoietic cells.  1,25-dihydroxyvitamin D3 can stimulate macrophage differentiation in 
U937 cells151.  Liu et. al. determined that a vitamin D3 response element in the p21 promoter is 
bound by the activated form of the vitamin D3 receptor (VDR) to stimulate p21 transcription.  
Retinoic acid (RA) induced monocytic differentiation of U937 cells has also been correlated to 
p21 transcriptional activation.  This effect occurs through binding of the retinoic acid receptor 
(RAR) to the RAR response element approximately 1.2 kilobases upstream of the p21 
transcriptional start site152.  An alternative mechanism of p21 transactivation has also been 
observed during monocytic differentiation.  IL-6 induced monocytic differentiation and G1 arrest 
of M1 leukemia cells is associated with downregulation of Gfi-1B expression, a DNA-binding 
transcriptional repressor, and derepression of the p21 promoter153.  Together, these studies 
demonstrate three independent mechanisms of p21 gene activation that occur in response to 
endogenous signaling molecules during monocytic differentiation, highlighting the importance of 
p21 to differentiation in this lineage.  Thrombopoietin (TPO) induced megakaryocytic 
differentiation is also accompanied by the upregulation of p21 transcription154.  Engagement of 
c-Mpl, the TPO receptor, triggers a signaling cascade mediated by JAK2 which results in 
activation of the STAT family of transcription factors155.  STAT proteins undergo tyrosine 
phosphorylation, become dimerized, and translocate to the nucleus where they activate gene 
expression (for review, 156,157).  Both STAT3 and STAT5 have been observed to undergo 
phosphorylation in response to TPO in CMK cells, a megakaryoblastic leukemia cell line, 
however, only STAT5 was found to bind to the p21 promoter.  Interestingly, p27 transcriptional 
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 upregulation, but not that of p21, has been shown to occur following G-CSF mediated activation 
of STAT3 in 32Dcl3 myeloid cells158.   
Several other cytokine induced signals converge upon STAT proteins to facilitate activation 
of p21 such as those stimulated by EGF, IFN-γ and IL-6.  Chin et. al. revealed that growth arrest 
stimulated by EGF or IFN-γ correlated with STAT1 activation and p21 transcriptional 
upregulation159.  This effect was shown to depend upon three STAT1 binding sites in the p21 
promoter.  In MG63 osteosarcoma cells, STAT1 and STAT3 were found to bind and activate the 
p21 promoter following induction of differentiation by IL-6 and IL-6 soluble receptor160.  More 
recent data shows that IL-6 induced p21 expression in a hepatoma cell line results from the 
simultaneous binding and cooperation of STAT3, the steroid receptor coactivator 1, 
NcoA/SRC1a, and p300/CBP on the p21 promoter161.  A follow-up study noted that PI-3 kinase 
pathway signals mediated the association of p300/CBP with STAT3 and NcoA/Src1a on the p21 
promoter following IL-6 stimulation in glioblastoma cell lines162.  PI-3 kinase inactivation 
prevented p300/CBP recruitment to the p21 promoter without altering the binding of STAT3 and 
NcoA/Src1a.  Inhibition of PI-3 kinase activity, by contrast, did not prevent the recruitment of all 
three factors to the c-Myc promoter, suggesting that constitutive activation of this pathway in 
transformed cells regulates growth arrest and proliferation through coordinated regulation of p21 
and c-Myc transcription. 
Direct protein interactions between p21 and c-Myc are responsible for reciprocal inhibition 
of each protein’s function, however c-Myc also operates at an additional level as a repressor of 
p21 transcription 49(for review, 163).  Although the p21 promoter does not contain the canonical 
c-Myc binding element (CACGTG or CATGTG), it does contain three E-box elements that 
conform to the CANNTG motif which are sufficient for binding by c-Myc:Max dimers164. In a 
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 study by Claassen et. al., c-Myc repression of p21 in fibroblasts acted through a region -62 bp 
and +16 bp of the p21 transcriptional start site, however direct binding of this sequence was not 
examined 165,166.  Another study demonstrated that expression and activation of c-Myc-estrogen 
receptor fusion proteins in p53 null fibroblasts could also suppress p21 transcription.  In vitro 
and in vivo binding studies suggested that suppression was mediated by c-Myc interactions with 
both Sp1 and Sp3165. 
Seone et. al. demonstrated that c-Myc is recruited to the -62 bp to +16 bp p21 proximal 
promoter region by the DNA-binding protein Miz-1 (Myc-interacting zinc finger 1)61.  Miz-1 has 
also been shown to be upregulated in multiple hematopoietic cell lines induced to undergo 
myeloid differentiation in response to TPA or retinoic acid167.  Miz-1 expression was sufficient 
to activate the p21 core promoter during differentiation of these cell lines.  The increase of Miz-1 
protein expression from basal levels during differentiation was correlated with a decrease in c-
Myc expression.  Furthermore, c-Myc was shown to associate with the p21 promoter and repress 
its activation through direct interaction with Miz-1.  The authors hypothesized that c-Myc and 
Miz-1 formed a repressor complex on the p21 promoter in undifferentiated cells, and that release 
of c-Myc from this complex was dependent upon differentiation signals.  A recent study using 
chromatin immunoprecipitation analysis (ChIP) concluded that c-Myc targets the methyl 
transferase Dnmt3a to the p21 promoter to form a repressive ternary complex with Miz-1168.  
Moreover, p21 repression by c-Myc was found to require DNA methylation activity.  These 
studies are consistent with the hypothesis that c-Myc specifically represses p21 transcription by 
multiple mechanisms to inhibit differentiation and promote cell proliferation. 
 
1.5.2. mRNA Stability and Regulation 
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 Regulation of messenger RNA turnover, like that of gene transcription, is a complex and 
important point of control that determines gene expression.  The structural features of an mRNA 
molecule, the 5’ and 3’ untranslated regions (UTRs), protein coding region and poly A tail, can 
all serve as docking points for RNA binding proteins.  Akin to transcription factors, these RNA-
binding proteins are trans-acting factors that regulate splicing, polyadenylation, localization, 
translation or degradation of a particular transcript.  Control of mRNA decay, once thought to 
occur in a non-specific fashion, is now known to be under tight regulation that is dependent upon 
evolutionarily conserved cis-acting sequences.  Alterations in mRNA half-life in response to 
environmental signals permit a cell to effect a rapid change in transcript abundance and therefore 
its acute physiologic response.  mRNA turnover is also an important regulatory element during 
differentiation and fetal development, as well as ongoing metabolic processes. 
Failure to ensure proper mRNA decay has been linked to several human diseases.  For 
example, short-lived transcripts encoding c-Myc, TNF-α, and many cell cycle regulatory 
proteins have altered stabilities due to 3’ UTR mutations which correlate with disease 
phenotypes169-172.  These pathologic states include cancer, cardiovascular disease, chronic 
inflammatory diseases, α-thalassemia and Alzheimer’s disease and are attributable to two 
principle causes.  First, the occurrence of sequence defects in 3’UTR cis-acting elements, and 
second, abnormal expression of the RNA-binding proteins that interact with these elements.  
Much data points to the importance of AU-rich cis-acting elements (AREs) in the 
regulation of short-lived transcripts.  Abundant in cytokine, transcription factor and cell cycle 
regulatory gene transcripts, AREs have been identified in ~1500 different genes to date173,174.  
Initial description of these motifs demonstrated that repeats of the AUUUA pentamer conferred a 
destabilizing effect upon the cytokine transcript GM-CSF175.  It has since been determined that 
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 triplets of the UUAUUUAUU nonamer are a more optimal destabilizing motif, however, this 
motif is not an absolute requirement since AU-rich elements that lack this sequence have been 
shown to be effective destabilizers176. 
The stability of a given ARE containing transcript depends upon two classes of trans-acting 
factors that work in opposition:  ARE stabilizers and ARE destabilizers.  The primary mRNA 
stabilizing proteins that have been studied are the Hu proteins: HuC, HuD (neuronal only) and 
HuR (ubiquitous) 177.  Hu protein overexpression is associated with poor outcomes in cancers 178-
181 .  Proliferation-associated transcripts that are stabilized by Hu proteins include cyclins A and 
B1 and c-fos 182,183.  Hu proteins may compete for binding with destabilizing proteins that 
recognize ARE sequences such as AUF1, KSRP and tristretraprolin (TTP) (e.g., 184). 
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Figure 3.  Human p21 mRNA:  Regulatory elements and RNA-binding proteins.  
Growth factor and stress stimuli trigger RNA:protein interactions which regulate p21 expression 
levels.  RNA-binding proteins interact with several conserved RNA-binding motifs residing in 
both the coding and 3’ untranslated regions of the p21 mRNA.  Competition for binding to these 
motifs regulates both p21 translation rates and p21 message stability.  (Inset)  Competition for 
access to AU-rich elements (ARE) between the mRNA stabilizing protein HuR and the mRNA 
destabilizer AUF1 has been hypothesized to represent a general phenomenon regulating mRNA 
stability184,185. 
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  p21 mRNA stability is regulated in response to various stimuli including UV radiation, 
phorbol ester, TNF-α, phenylephrine, EGF and Prostaglandin A2186-191.  Elements responsive to 
these stimuli are localized to the 3’ UTR and include three AREs which contain the AUUUA 
pentanucleotide.  Endogenous RNA binding proteins have been shown to bind these elements 
and include HuR, AUF1, NF90 and CP1192-194.  Lethal defects in skeletal muscle formation in 
NF90-/- knockout mice were correlated with dramatic reductions in p21, MyoD and Myogenin194.  
Increased apoptosis and skeletal muscle abnormalities are also observed in p21/p57 double 
knockout mice111.  These findings are consistent with the hypothesis that NF90 stabilization of 
p21 through binding its AREs is an important component of myogenesis.  While CP1 binding 
was not attributable to a specific stimulus, binding of HuR to p21 ARE containing regions occurs 
in response to UV radiation, induction of myocyte and neuronal differentiation and Prostaglandin 
A2 treatment189,195,196.  Each of these stimuli caused a substantial increase in the cytoplasmic 
abundance of HuR, where it is thought to exert the majority of its mRNA stabilizing effect, and 
correlated with increased p21 mRNA binding and stabilization.  However, HuR mRNA binding 
is not limited to the cytoplasm.  In a study by Lal and colleagues in HeLa cells (cervical 
carcinoma), HuR and AUF1 binding to p21 mRNAs occurred in the nucleus.  While both 
proteins could bind p21 transcripts in the nucleus, competitive binding of one or the other 
directed cytoplasmic p21 transcripts either to the polysome for translation or to the exosome for 
degradation  184.  Interestingly, independent suppression of HuR or AUF1 with siRNA 
demonstrated that each could bind the preferred site of the other; indicating that competition 
between HuR and AUF1 is a function of their relative expression levels.  Further analysis 
revealed that upon UV irradiation, increased cytoplasmic HuR was found in association with 
polysome bound p21 mRNA in the absence of AUF1, suggesting that common targeting was a 
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 phenomenon limited to the nuclear compartment.  AUF1 has been found to interact with 
components of the exosome, a multisubunit machine responsible for 3’-5’ mRNA degradation, 
and decay of AU-rich mRNAs has been associated with AUF1 ubiquitination and its proteasomal 
degradation197,198.  Since cytosolic AUF1 copurified with exosomal components in ribosome free 
fractions, it was hypothesized that in the absence of UV stabilizing signals, AUF1 shuttles p21 
mRNA to the exosome for decay, thus preventing p21 protein accumulation and growth arrest. 
Competitive regulation of p21 translation also occurs and is mediated by RNA binding 
proteins that interact with ARE-independent elements.  A GC-rich region in the p21 coding 
region can form a stem loop structure which contains a conserved CUG triplet.  CUG binding 
protein 1 (CUGBP1), a protein implicated in the pathogenesis of the CUG triplet expansion 
disease myotonic dystrophy, was found to interact with this stem loop in a phosphorylation 
dependent manner  CUGBP1 binding promoted p21 translation and a senescent phenotype in 
fibroblasts53,199.  Calreticulin was demonstrated to also bind this GC-rich stem loop, functioning 
to repress p21 translation and promote proliferation.  Competition between CUGBP1 and 
Calreticulin for binding the stem loop was shown to control the onset of senescence in this 
system. 
Within the p21 3’ UTR, there are several CU-rich regions that can be targeted by KH-
domain containing proteins.  The KH-domain, so named for the KH domain in hnRNP K, is an 
RNA-binding domain that has been conserved throughout evolution in both prokaryotes and 
eukaryotes200.  Recent work utilizing a neuroblastoma model of neuronal differentiation showed 
that upregulation of p21 protein expression during differentiation was a function of translational 
control mediated by CU-rich elements in the p21 3’UTR195.  Whereas overexpression of HuR 
was found to promote increases in p21 protein expression and neuronal differentiation, 
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 exogenous hnRNP K inhibited both without alteration of mRNA stability.  Optimal binding of 
hnRNP K occurs in sequence elements containing the UC3-4UA/AU motif201.  Three UC3-
4UA/AU motifs are present in the human p21 3’UTR, one of which is in close proximity to the 
AREs (Fig. 3).  hnRNP K was found to bind the p21 3’UTR and could inhibit p21 translation of 
reporter genes containing this sequence.  Because HuR and hnRNP K were found to associate 
within endogenous complexes and bind each other in vitro, the authors hypothesized that 
translational blockade in undifferentiated neuroblastoma cells was mediated by hnRNP K 
recruitment to the p21 3’UTR through interactions with HuR. 
Regulation of p21 transcripts is not limited to interactions with RNA-binding proteins.  
Sequence specific targeting of microRNAs (miRNA) to mRNA transcripts has emerged as a 
mechanism that controls mRNA stability and translation.  Regulation of cell growth, apoptosis 
and differentiation of neural and hematopoietic tissues are recently described functions of 
miRNA genes202.  In addition, pluripotency in murine embryonic stem (ES) cells is associated 
with expression of specific miRNAs which become downregulated upon differentiation203.  
Mature 22-bp miRNAs are generated through Drosha endonuclease-mediated processing of a 
long polymerase II-transcribed pri-miRNA in the nucleus followed Dicer endonuclease-mediated 
cleavage of a ~80 bp pre-miRNA in the cytoplasm204.  A recent study of Drosophila 
melanogaster germline stem cells (GSCs) carrying mutant forms of dicer-1 revealed defects in 
germline cyst development and in G1 to S phase transitions due to elevated expression of the 
Drosophila CDKI Dap, a protein homologous to p21 and the cip/kip family proteins205.  A partial 
phenotypic rescue of cyst production and restoration of Cyclin E levels in GSCs was 
accomplished by mutation of Dap genes to remove predicted miRNA binding sites in the 3’UTR.  
Because Dap expression was similarly reduced in GSCs containing either mutant dicer-1 or the 
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 mutant Dap transgene, this suggests that the miRNA pathway plays a role in cell cycle control 
and Dap expression through a post-transcriptional regulatory mechanism in GSCs.   It is 
conceivable that p21 regulation of mammalian stem cell cycling is also under the control of 
miRNAs acting on the p21 3’UTR. 
In summary, post-transcriptional regulation of mRNA stability and translation is dependent 
upon both cis-acting elements and trans-acting factors.  Regulated sequences in the p21 mRNA, 
mainly in the 3’UTR, include AU-rich elements that are targets for stabilization of short-lived 
transcripts, as well as CU-rich elements and CUG containing stem loops that control translation.  
These elements are bound by several distinct trans-acting factors whose binding, and effects, 
may be controlled through competition.  Cytokines, cellular stressors and differentiation all can 
evoke changes in p21 message stability and p21 translation in both cell lines and animal models.  
Furthermore, there is provocative evidence from Drosophila studies which suggests that 
miRNAs may contribute to p21 translation control during GSC division through putative miRNA 
binding motifs in the 3’UTR.  It has become clear that p21 expression is under complex control 
at the posttranscriptional level.  This facilitates rapid coupling of p21 expression to 
environmental cues.    A large network of regulatory proteins and perhaps small RNAs act both 
to control p21 mRNA stability and p21 protein turnover (see below).   
 
1.5.3. p21 Protein Stability and Posttranslational Modification 
1.5.3.1. Phosphorylation 
p21 protein functions are governed by its stability, intracellular localization and the range of 
its binding partners.  In broad terms, regulation of these characteristics is achieved within a cell 
very often through posttranslational modification.  There are numerous functional groups that are 
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 covalently attached to proteins to modify charge, conformation, and hydrophobicity including 
phosphates, sugars, lipids, methyl groups and small proteins such as ubiquitin.  p21 has been 
described to undergo both phosphorylation and ubiquitination. 
Phosphorylation of p21 by the serine/threonine kinase Akt/PKB has been shown to occur 
on two adjacent C-terminal residues, Thr145 and Ser146, which reside within an Akt 
phosphorylation motif 206-208.  Akt lies within the PI-3 kinase signaling pathway, is activated by 
phosphoinositides, a class of small phospholipids generated by upstream kinases, and regulates 
growth, survival and metabolism in many cell types.  Scott et. al. utilized surface plasmon 
resonance and in vitro binding studies to show that p21:PCNA interactions were dependent upon 
the phosphorylation state of Thr145 and Ser146206.  Phosphorylation at these sites prevented p21 
binding to PCNA.  Further examination of this phenomenon in endothelial cells showed that 
PCNA binding was disrupted when p21 was phosphorylated at Thr145 by Akt209.  In this study, 
Thr145 phosphorylation limited the ability of p21 to inhibit DNA replication.  In addition, data 
suggested that phosphorylation at this site led to decreased binding and repression of Cdk2, 
indicating that Thr145 phosphorylation serves to inactivate multiple mechanisms by which p21 
inhibits cell proliferation.  C-terminal phosphorylation of p21 at Ser146 was also found to be 
catalyzed by atypical protein kinase-ζ (PKCζ)210.  Like Akt, PKCζ activity is thought to regulate 
growth, survival and differentiation, as well as regulate metabolic responses to insulin (for 
review, 211.  However, unlike Akt, PKCζ was found to only phosphorylate Ser146, and not 
Thr145, by in vitro kinase assay, doing so with a much higher affinity than Akt.  In cell line 
experiments, overexpression of PKCζ resulted in a shortening of p21 protein half-life.  
Furthermore, it was found that an acute and transient decrease in p21 protein levels following 
insulin treatment of HCT116 cells (colon carcinoma) was dependent upon PKCζ activity.  These 
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 experiments suggest that Ser146 phosphorylation by PKCζ is a signal to increase p21 protein 
turnover in vivo and comprise a pathway through which acute changes in metabolic states are 
coordinated with regulation of cell cycle modulators.  In glioblastoma cells, phosphorylation by 
Akt occurs at Thr145 and Ser146.  Thr145 phosphorylation in this system confirmed an 
inhibition of p21:PCNA binding.  While PKCζ-mediated phosphorylation at Ser146 caused a 
decrease in p21 half-life in colon carcinoma cell lines, Akt phosphorylation of this site, by 
contrast, was shown to increase the half-life of p21 protein and was associated with increased 
resistance to Taxol-induced apoptosis208.  In transfection experiments using p21-/- MEFs, Akt 
activated by HER-2/neu overexpression was shown to phosphorylate p21 at Thr145 and result in 
p21 cytoplasmic relocalization.  Using phospho-specific antibodies directed at Thr145 in HER-
2/neu positive primary adenocarcinomas, phosphorylated forms of p21 were found to localize to 
the cytoplasm and were correlated with poor survival55,212.  These studies demonstrate that 
survival signals integrated by Akt can regulate p21 phosphorylation state and abundance, in a 
cell type-specific manner, and thereby provide a regulatory mechanism of p21 anti-apoptotic 
function. 
A countervailing mechanism could be mediated by glycogen synthase kinase-3β, a protein 
phosphorylated by Akt at Ser21/Ser9 to inhibit its activity212.  GSK-3β regulates many 
intracellular metabolic processes including protein synthesis and breakdown (for review, 213).  In 
vitro phosphorylation of p21 by GSK-3β was shown to occur at Thr57 and overexpression of 
GSK-3β in human umbilical vein endothelial cells (HUVEC) was correlated with decreased 
expression of p21 protein.  These observations create a possible scenario whereby opposing 
activities of Akt and GSK-3β control p21 protein levels to serve as one determinant of cell 
survival. 
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 Recent data indicates that Thr57 phosphorylation, as well as phosphorylation at Ser130, 
may control p21 cell cycle effects.  Dash et. al. determined that p21 undergoes a transient 
hyperphosphorylation at the G2/M phase of the cell cycle and that hyperphosphorylated p21 
associated with CyclinB1-Cdc2 complexes214.  Using a Thr57 phosphomimetic mutant of p21, 
p21 T57D, in p21-/- cells, they showed that cyclin B1 binding of this mutant was required for 
cyclin B1-associated kinase activity in G2/M.  Their data suggests that Thr57 phosphorylation 
can specify p21:Cdk associations and promote kinase activation at the G2/M checkpoint.  In 
HD3 colon carcinoma cells, p21 phosphorylation was shown to occur in response to TGF-β1 
stimulation, resulting in an increase in p21 protein stability and growth arrest215.  In vitro 
analysis determined that both JNK1 and p38α were p21 kinases.  However, phosphopeptide 
mapping determined that only p38α was able to phosphorylate p21 both in vitro and in vivo 
following TGF-β1 stimulation, doing so at Ser130.  Together, these findings link 
phosphorylation of p21 to protein stability as a transcription-independent phenomenon of cell 
cycle regulation.  It should be noted that we have generated stable aspartate and alanine mutants 
of p21 phosphorylation targets (Thr145, Ser 146, and Thr57) but found that mutations did not 
alter p21 subcellular distribution in 32Dcl3 cells (data not shown). 
 
1.5.3.2. Proteolysis and Ubiquitin 
 
A major determinant of p21 protein stability is its rate of decay.  Proteolysis of p21 is 
mediated by the proteasome, a multisubunit ATP-dependent protease.  The proteasome is a 
polysubunit cylindrical structure with a 20S core complex containing protease activity and a 19S 
regulatory complex that detects and recruits ubiquitinated proteins and caps each end.  The 
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 covalent addition of ubiquitin (ubiquitination) to proteins is often a precursor step that targets 
proteins for proteasomal destruction.  It has been well documented that p21 protein levels and 
half-life can be increased through the use of proteasomal inhibitors 216-218.  The ubiquitination of 
p21 occurs, but it is not the only mechanism that is correlated with p21 stability.  The cellular 
setting and type of decay signals are also important parameters. 
Protein ubiquitylation occurs over several steps and is mediated by at least three different 
enzymes.  This pathway begins with free ubiquitin becoming activated by an E1 or ubiquitin 
activating enzyme.  Next, ubiquitin is transferred to a ubiquitin-conjugating enzyme (E2).  In the 
final step, a ubiquitin protein ligase (E3) transfers ubiquitin from E2 to the substrate by 
catalyzing a covalent linkage between ubiquitin and the ε-amino group of a lysine residue on the 
substrate.  Continuous ubiquitination results in the formation of polymeric ubiquitin chains on 
the substrate.  Efficient proteasomal targeting requires a chain with a minimum of four ubiquitin 
subunits219.  This is important because the addition of a single ubiquitin tag can have functional 
consequences independent of protein fate (for review, 220).  There are numerous E1, E2 and E3 
class proteins, with substrate specificity most often defined by interactions with E3 ubiquitin 
ligases.  One notable E3 ligase complex, the Skp1/Cullin/F box protein-related complex (SCF) 
controls the abundance of some cell cycle regulatory proteins, notably p27 and p57221,222.  SCF-
mediated ubiquitin conjugation of p21 occurs in vitro and may be responsible for S phase 
destabilization of p21223.   
Although ubiquitinated forms of p21 have been described, controversy remains over 
whether ubiquitination is necessary for basal p21 turnover by the proteasome.  Sheaff et. al. used 
a lysine-free form of p21, which had its six lysine residues mutated to arginine, to determine if 
ubiquitination was a requirement for p21 proteasomal decay218.  This mutant protein was shown 
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 to retain its CDK-inhibitory properties, did not form ubiquitin conjugates, and had a short half-
life, similar to that of wild-type p21.  Moreover, its abundance underwent a significant increase 
in response to treatments with proteasomal inhibitors, indicating that p21 ubiquitination was not 
an absolute requirement for proteasomal turnover.  Interestingly, mechanistic support for this 
finding arose in a study by Touitou et. al. where they demonstrated that purified 20S proteasome 
subunits could mediate ubiquitin-independent proteolysis of p21.  They found that the last 31 
amino acids of the p21 C-terminus were required for the effect and were responsible for direct 
binding to the C8 α-subunit (C8α) of the 20S proteasome 224.  A complementary study 
determined that introduction of the H-Ras oncogene into fibroblasts resulted in a Cyclin D1 
dependent increase in p21 protein stability225.  It was further demonstrated that Cyclin D1 could 
block interactions between p21 and C8α and that titration of Cyclin D1 could inhibit p21 
proteolysis by purified 20S proteasomes.  These studies suggest that a pathway for p21 
degradation exists where the ubiquitin detection machinery in the 19S proteasomal subunits can 
be bypassed.  In light of these findings however, a recent and provocative study suggests that p21 
ubiquitination is required for proteasomal degradation226.    Ubiquitin mutants that cannot form 
polyubiquitin chains were used to show that in vivo degradation of wild-type and lysine free p21 
was dependent on a functional ubiquitin system.  Moreover, lysine residues were found to be 
dispensable since in vivo ubiquitination was found to occur on the amino group of the N-terminal 
methionine in both wild-type and lysine-free p21 mutants and suggested that the sensitivity of 
previous ubiquitin analyses was insufficient.  Nonetheless, further experimentation will be 
required to reconcile these conflicting observations. 
The E3 ubiquitin ligase MDM2 is an oncoprotein that mediates p53 ubiquitination and 
targeting to the proteasome for destruction227.  Like p21, MDM2 transcription is activated by 
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 p53, however it operates in negative feedback to regulate p53 levels.  Simultaneous and 
independent studies addressed the hypothesis that MDM2 inhibits p53-induced G1 arrest by also 
regulating p21 protein levels.  These studies determined that MDM2 could interact with p21, 
reduce p21 half-life independent of ubiquitin transfer and could promote p21:C8α association in 
vitro228,229.  MDM2 binding to p21 may be the physical bridge that links p21 with the 20S 
proteasomal machinery in vivo, and sets up a mechanism whereby MDM2 competition with p21 
stabilizing proteins determines its expression level.  In fact, recent work identified WISp39 as a 
novel p21 interacting protein that can prevent p21 proteasomal degradation.  WISp39 was shown 
to bind the N-terminus of p21 and recruit Hsp90, via a tetratricopeptide (TPR) domain, into a 
ternary complex with p21.  Absence of the TPR domain resulted in a loss of Hsp90 recruitment 
and loss of p21 stabilization.  Moreover, p21 stabilization and growth arrest responses to ionizing 
radiation damage did not occur when WISp39 levels were reduced with siRNA or when Hsp90 
was inhibited with Geldanamycin. This finding suggests that both p53 transcription and 
molecular chaperones are necessary to stabilize p21 following ionizing radiation and reinforces 
the hypothesis that competition between stabilizing and destabilizing interactions determines the 
net balance of p21 protein expression.  This contrasts with a study by Bendjennat et. al., where it 
was found that low, and not high, doses of UV radiation caused a ubiquitin-dependent 
degradation of p21230.  They showed that p21 ubiquitination was also dependent upon ATR 
activation and Skp2 ubiquitin ligase activity, and that lysine-free mutants of p21 did not get 
degraded following the UV stimulus.  Because sustained levels of the lysine-free p21 mutant 
inhibited DNA repair, it may be that a ubiquitin-dependent pathway of p21 decay is selectively 
activated by the DNA repair machinery when DNA damage is not overwhelming, as is often the 
case in the setting of ionizing radiation. 
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 1.6. IL-3 in Myelopoiesis and Acute Myeloid Leukemia 
 
The growth factor Interleukin-3 (IL-3) is a pleiotropic cytokine protein that can promote the 
survival and proliferation of multipotent hematopoietic progenitors, as well as stimulate the 
development of multiple hematopoietic lineages231-233.  IL-3 is mainly produced by activated T 
cells, whereas bone marrow stromal cell production has not been reported234.  The human IL-3 
receptor (IL-3R) is a heterodimer consisting of an α chain (IL-3Rα) and a common β chain (βc) 
which is the primary signal transducing subunit in the complex.  The common β chain is shared 
with the GM-CSF and IL-5 receptors.  Mice encode both a common β chain (βc) and an IL-3 
specific β chain (βIL-3).  Homozygous deletion of the βIL-3 chain or IL-3 genes in mice results in 
no hematopoietic impairments235,236.   This may be due to compensatory signals provided by 
GM-CSF and M-CSF, cytokines known to synergize with IL-3 to increase cell cycling and 
proliferation of bone marrow progenitors237,238. 
 IL-3 promotes development of all myeloid lineages, but acts in opposition to 
development of lymphoid progenitors239-241.  Most effective as a stimulator of granulocyte and 
monocyte colony formation (CFU-GM), IL-3 also contributes to eosinophil, mast cell, 
megakaryocyte and erythroid colony formation238,242-244.  IL-3 is thought to be the main survival 
and differentiation factor for basophils245,246.  In contrast to mast cells, circulating mature 
basophils express the IL-3R and can be activated to release histamine in response to IL-3247. 
Studies have demonstrated high expression levels of the IL-3 receptor in acute myeloid 
leukemias (AML), including leukemic stem cell populations22,248.  IL-3 can activate DNA 
synthesis and proliferation in  primary AML cells, as well as support self-renewal by promoting 
growth of AML-colony forming cells249,250.  Primary AML cells with high IL-3Rα expression 
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 have also been correlated with resistance to growth-factor withdrawal and increased cell 
cycling251.  Moreover, patients were found to have higher levels of leukemic blasts at diagnosis, 
reduced rates of complete remission and decreased overall survival.  These studies demonstrate 
the biological and clinical importance of IL-3 signaling pathways in myeloid development and 
myeloid malignancy. 
 Ligation of the IL-3 receptor results in the rapid activation of several signal transduction 
pathways.  These include the Janus kinase (JAK)/STAT pathway, mitogen-activated protein 
kinase (MAPK/ERK) pathway and the PI-3 kinase pathway 252.  The Src-family of tyrosine 
kinases, notably c-Src, Hck, Fyn and Lyn, have also been reported to be activated by IL-3 in 
myeloid cells253,254.  IL-3 regulates transcription through these pathways to stimulate the 
production of immediate-early genes such as c-Myc, c-Fos and c-Jun which are responsible for 
the survival, differentiation and proliferative effects of IL-3252,255.  There is a sole report 
indicating that IL-3 contributes to gene stability at the post-transcriptional level.  In mature 
human eosinophils, IL-3 was shown to stabilize the mRNA of its own receptor subunits, the IL-
3Rα and βc chains256.  Despite this observation, there has been no systemic study of 
posttranscriptional regulatory mechanisms controlled by IL-3. 
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2.1. Abstract 
 
p21waf1/cip1 (p21), best known for its ability to regulate the cell cycle, has been noted also to exert 
cell-cycle-independent effects on apoptosis and differentiation.  Inhibition of apoptosis by p21 
has been reported in hematopoietic models, particularly in monocytes exposed to apoptogenic 
agents.  The effect of p21 on survival has not hitherto been analyzed during the myeloblast to 
granulocyte transition.  Using 32Dcl3 murine myeloblasts, a cell line that proliferates in IL-3 and 
differentiates in G-CSF, we studied the effects of forced expression of p21 on cell survival.  We 
hypothesized that exogenous p21 would suppress the modest levels of cell death associated with 
G-CSF mediated differentiation of 32Dcl3 cells.  Contrary to expectations, we found that 
exogenous p21 enhanced apoptosis of cells removed from IL-3.  p21 overexpression led to 
decreased cell growth, caspase 3 activation and annexin-V positivity.  These effects occurred 
only in the presence of G-CSF.  These findings suggest that p21 is proapoptotic in 
granulopoiesis, and that this effect is masked by IL-3-mediated survival signals.  Our results also 
indicate there are distinct and opposing effects of p21 on monocytic and granulocytic survival.  
Aberrantly high levels of p21 may contribute to disease processes involving excessive apoptosis 
of granulocyte precursors.  
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 2.2. Introduction 
The multifunctional molecular adaptor protein p21waf1/cip1 (cdkn1a, hereafter p21), best 
known for its ability to regulate the cell cycle, has been noted also to exert cell-cycle-
independent effects on differentiation 81,97,103,122 and on apoptosis.  Inhibition of apoptosis by p21 
has been reported in nonhematopoietic and in hematopoietic models (reviewed in 56).  In the 
U937 monocytic cell model, p21 is upregulated concurrent with vitamin D-mediated 
differentiation.  Ectopic p21 localized to the cytoplasm and prevented cell death by stress-
signaling pathways and by autocrine TNF-α production 63,81.  We have previously demonstrated 
that p21 decreased chemotherapy-mediated apoptosis of K562 myeloid cells by preventing 
etoposide-induced degradation of the anti-apoptotic protein cIAP1 79.  Other mechanisms 
proposed for anti-apoptotic action of p21 include procaspase-3 inhibition 76 and ASK1 inhibition 
81.  A physiologic anti-apoptotic function of p21 in hematopoiesis is supported by the finding that 
exogenous p21 overexpression in CD34+ cells increases CFU-GEMM formation 257.  Moreover, 
high levels of endogenous p21 are linked to chemoresistance and poor prognosis in AML 3,257.  
In aggregate, these reports indicate that p21 antagonizes apoptosis, particularly apoptosis 
triggered by p53 activation (for review, 56).  
During monocytic differentiation of the U937 cell line, p21 levels increase and p21 
localizes to the cytoplasm where it is retained by the BRAP2 protein 81,258.  Cytoplasmic p21 
inhibits apoptosis in U937 monocytes by binding to and inactivating ASK1 kinase, an 
intermediary in the JNK stress signaling pathway 81.   Normal human monocytes express 
exclusively cytoplasmic p21, supporting a physiologic function of p21 identical to that 
uncovered in cell line experiments 81. 
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 In contrast to the p21 expression pattern in monocytes, we have demonstrated that p21 
protein levels are high in normal human myeloblasts but decline when blasts commit to terminal 
differentiation despite sustained levels of p21 gene transcription 99.   Because neutrophils are 
shorter-lived than monocytes we speculated that the observed downmodulation of p21 during 
granulopoiesis may contribute to an increased sensitivity of differentiating granulocytes to 
apoptotic stimuli.  A role for p21 in apoptosis during granulopoiesis has not hitherto been 
studied. 
The murine 32Dcl3 myeloblast cell line was chosen to model p21 effects during 
granulopoiesis.  This cell line proliferates in IL-3 and differentiates to neutrophils upon 
substitution of G-CSF for IL-3.  As noted herein, 32Dcl3 differentiation recapitulates the 
expression pattern of p21 in normal granulocytic precursors with decreased p21 protein levels 
following initiation of differentiation.  We expected that increasing p21 expression with 
exogenous p21 would inhibit apoptosis in these cells, as reported for monocytic U937 cells.  
Contrary to expectations, we found that exogenous p21 increased cell death during myelopoiesis. 
The increase in cell death was manifested in the presence of G-CSF but not while cells were 
proliferating in IL-3.  These findings suggest that p21 is proapoptotic in granulopoiesis, and that 
this effect is masked by IL-3-mediated survival signals or by modification of p21 by IL-3.  
Downmodulation of p21 may be required to maximize the survival of granulocyte precursors 
after the myeloblast stage. 
 
 
2.3. Materials and Methods 
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2.3.1. Cells and Culture 
32Dcl3 cells (32D)259 (kind gift from Alan Friedman, Johns Hopkins University) were 
cultured in RPMI 1640 media supplemented with 10% fetal bovine serum, penicillin-
streptomycin (100 I.U./ml and 100 ug/ml) and 2 mM L-Glutamine (Mediatech, Herndon, VA).  
Murine IL-3 (Peprotech, Rocky Hill, NJ) was used at 2 ng/ml during cell passaging.  Serum and 
murine IL-3 are required for survival, proliferation and maintenance for the myeloblast 
phenotype of these cells in culture 4. Unless otherwise noted, all experiments were carried out 
with cells maintained between 2x105 and 1x106 cells/ml, to minimize paracrine effects that may 
occur at density extremes, and incubated at 37°C with 5% CO2.  Phoenix A cells (ATCC, 
Manassas, VA), an amphotropic retroviral packaging cell line, were cultured in DMEM 
(Mediatech, Herndon, VA) with fetal bovine serum, penicillin-streptomycin and L-glutamine as 
noted above. 
2.3.2. Differentiation 
To induce differentiation, 32D cells were washed twice with 50 ml PBS to remove IL-3, 
resuspended in cytokine free media at 2x105 cells/ml and incubated for 4 hours, followed by 
addition of G-CSF (Amgen, Thousand Oaks, CA) to a final concentration of 100 ng/ml.  Cell 
viability and viable cell density was determined immediately prior to G-CSF addition by trypan 
dye exclusion assay using a Vi-Cell XR cell viability analyzer (Beckman-Coulter, Miami, FL) 
and was evaluated every 24 hours thereafter.  Differentiation was confirmed by analysis of 
Wright-Giemsa stained cytospins at each time point assessed. 
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 2.3.3. Statistics 
Viability and cell growth characteristics were compared to negative controls with 
significance determined by a 2-tailed, type 2 student’s t-test using 95% confidence intervals.  All 
calculations were made using the Excel software package (Microsoft, Redmond, WA).  
2.3.4. Plasmids 
Retroviral constructs were derived from the MIG plasmid (a kind gift of Luk Van Parijs, 
Massachusetts Institute of Technology), which contains an IRES-GFP cassette downstream of its 
multiple cloning region.  Using standard methods, the Gateway® vector conversion cassette 
(Invitrogen, Carlsbad, CA), reading frame B, was blunt-end cloned into the MIG Hpa I site and 
transformed into DB3.1 cells (Invitrogen) to create a Gateway® destination vector, MIGccd.  
Human p21 wild-type cDNA (accession# NM_078467) carrying a myc-his tag was PCR 
amplified and cloned into the pENTR-D-TOPO (Invitrogen) plasmid to create a Gateway® entry 
vector, pENTR-D hp21WT.  The expression clone MIG hp21WT was synthesized by combining 
pENTR-D hp21WT and MIGccd in an LR clonase recombination reaction (Invitrogen) per 
manufacturer’s instructions.  The expression clone MIG CTL was synthesized by combining 
pENTR-D and MIGccd in an LR clonase recombination reaction.  All plasmids were verified by 
sequencing analysis.  
2.3.5. Retroviral Transduction 
To generate retroviruses for infection of 32D cells (protocol modified from 260), Phoenix A 
cells were transfected with retroviral MIG plasmids using the Polyfect Transfection Reagent 
(Qiagen, Valencia, CA).  Phoenix cells were plated at a density of 2.5x106 cells/dish in 60 mm 
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 dishes and incubated for 16 hours.  For each dish, 4 µg plasmid DNA was mixed with 40 µl 
Polyfect, incubated and applied to the cells per manufacturer’s instructions for 60mm dishes.  
Transfection media was removed after 24 hours of incubation at 37°C and 4 ml fresh DMEM 
was added.  Cells were incubated at 32°C for an additional 48 hours.  Viral supernatants were 
harvested and passed through a 45 µM syringe filter to exclude producer cells.  Viral 
supernatants were supplemented with 2 ng/ml murine IL-3 and 8 µg/ml polybrene (Sigma-
Aldrich, St. Louis, MO).  2x105 32D cells were pelleted and resuspended in 4 ml of viral 
supernatant and aliquoted into one well of a 6-well plate.  Using a microplate carrier, cells were 
centrifuged at 32°C for 90 minutes at 2500 RPM (H1000b rotor, Sorvall RT6000D centrifuge).  
Cells were incubated overnight at 32°C and placed in fresh viral supernatant with IL-3 and 
polybrene.  Centrifugation was repeated and cells were cultured at 32°C for 24 hours.  Following 
this incubation period, cells were pelleted, the viral supernatant was replaced with IL-3 
supplemented RPMI growth media and the cells were incubated for an additional 48 hours at 
37°C.  Transduced cells were sorted on the basis of GFP expression using a Cytomation MoFlo 
(Cytomation, Fort Collins, CO).  To derive clonal populations, one cell per well sorting 
parameters were used, isolating cells in a 96-well plate.   
2.3.6. Western Blotting 
Protein samples were prepared using two methods.  For comparison of relative transgene 
expression in clonal lines, 32Dcl3 extracts were prepared in modified RIPA buffer (50 mM Tris-
HCl pH 7.4, 150 mM NaCl, 0.25% Na-Deoxycholate, 1.0% NP-40, 1 mM EDTA, 1 mM PMSF, 
1 mM NaF, 0.5 mM DTT, 1.0 mM Vanadate, 1:250 Protease Inhibitor Cocktail (Sigma-Aldrich, 
Cat:  P-8340) and quantified using a BCA protein assay (Pierce, Rockford, IL).  To minimize 
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 upregulated protease activity in cells stimulated with G-CSF, either 1.5x105 or 3.0x105 cells were 
harvested, washed once in ice-cold PBS, lysed directly in 15 µl 2X sample buffer (0.125 M Tris-
HCl pH 6.8, 4% SDS, 20% Glycerol, 2% 2-mercaptoethanol, 0.03 mM Bromphenol Blue), and 
boiled for 5 minutes.  Lysates containing equal amounts of total protein were run on 12% SDS-
PAGE gels.  Alternatively, an equivalent number of whole cells, lysed directly in 2x sample 
buffer, were analyzed by SDS-PAGE.  Proteins were electrotransferred onto Protran membranes 
(Schleicher and Schuell, Keene, NH), which were incubated with Ponceau S (Sigma-Aldrich) to 
confirm transfer efficiency.  Membranes were then incubated with blocking buffer (5% w/v 
nonfat dry milk, 1x TBS, 0.1% Tween-20) for 1 hour.  Antibodies were diluted in blocking 
buffer and included goat polyclonal p21(C-19)-HRP (1:1000, Cat: SC-397HRP, Santa Cruz 
Biotechnology, Santa Cruz, CA), mouse monoclonal β-Actin (AC15) (1:20,000, Cat:  A5441 
Sigma-Aldrich), mouse monoclonal p27-HRP (1:2500, Cat:  K25025, BD Transduction 
Laboratories, San Diego, CA), mouse monoclonal α-Tubulin (DM1A) (1:2500, Cat:  T9026, 
Sigma-Aldrich), mouse monoclonal Lamin B1 (1:1000, Cat:  33-2000, Zymed, San Francisco, 
CA), and rabbit polyclonal cleaved Caspase-3 (1:1000, Cat:  9661, Cell Signaling Technology, 
Beverly, MA).  Where appropriate, secondary HRP-conjugated antibodies were diluted in 
blocking buffer and included goat anti-mouse IgG (H + L)-HRP (Cat:  170-6516, Bio-Rad, 
Hercules, CA) and goat anti-rabbit IgG (H + L)-HRP (Cat:  170-6515, Bio-Rad).  Signals were 
developed using the Western Lightning chemiluminescence reagent (PerkinElmer, Boston, MA).  
Scanned images of exposed film underwent signal density analysis using Image J 1.31v software 
(http://rsb.info.nih.gov/ij). 
2.3.7. Northern Blotting  
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 RNA was prepared from 1x107 32D cells propagating in IL-3, cytokine starved for 4 hours, 
or stimulated with G-CSF for each time point analyzed using RNeasy total RNA purification kits 
(Qiagen, Valencia, CA).  Blots were performed as described previously 95.  In brief, radiolabeled 
probes were prepared at 1x106 CPM/ml hybridization buffer, incubated with membranes 
overnight, washed and subjected to autoradiography at -80°C for 1-5 days.   The murine p21 
probe contained nucleotides 100-578 (Genbank Accession # NM_007669) which were amplified 
by PCR using the following primers:  forward – CACCATGTCCAATCCTGGTGATG, reverse 
– TCAGGGTTTTCTCTTGCAGAAG.  The GAPDH probe was human in origin and contained 
nucleotides 100-941 (Genbank Accession #NM_002046) which were amplified by PCR using 
the following primers:  forward – AACGGATTTGGTCGTATTGGG, reverse – 
TCGCTGTTGAAGTCAGAGGAGAC.  Scanned images of exposed film underwent signal 
density analysis using Image J 1.31v software (http://rsb.info.nih.gov/ij).  Multiple exposures 
were obtained to optimize linearity of signal. 
 
2.3.8. Cell Cycle Analysis 
Cell cycle distribution and DNA content were determined by measurement of propidium 
iodide uptake in ethanol-fixed cells using a Coulter EPICS XL flow cytometer and Expo32 ADC 
software (Beckman Coulter, Miami, FL).  Treated 32D cells were washed once, resuspended in 
0.5 ml PBS, transferred to ice-cold 70% ethanol to a final density of 1x106 cells/ml and stored at 
-20°C overnight.  For each sample, one million fixed cells were washed once in 5 ml PBS, 
resuspended in 1 ml propidium iodide staining solution (20 µg/ml propidium iodide, 200 µg/ml 
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 RNase A, 0.1% Triton X-100 in PBS), incubated in the dark at 37°C for 15 minutes, and 
analyzed. 
2.3.9. Annexin-V/Sytox Blue Staining 
Apoptosis was assayed using the Annexin V-PE Apoptosis Detection Kit I (Cat:  559763, 
BD Pharmingen, San Diego, CA) with modification.  7-Amino-Actinomycin-D (7-AAD) was 
substituted with Sytox Blue nucleic acid stain (Cat:  S-11348, Molecular Probes, Eugene, OR).  
1x105 cells resuspended in 100 µl 1x binding buffer per manufacturer’s instructions were treated 
with 5 µl Annexin-V PE solution and Sytox Blue was titrated to 1 µM.  Following a 15 minute, 
room temperature incubation in the dark, 400 µl of 1x binding buffer was added and the cells 
were analyzed using a CyAn LX flow cytometer (DakoCytomation, Fort Collins, CO) and the 
Summit software package (DakoCytomation). 
 
2.4. Results 
 
 
2.4.1. p21 downregulation by G-CSF in 32D cells 
To determine if p21 protein levels were modulated in 32D cells during differentiation, p21 
temporal expression patterns were examined in cells stimulated to differentiate with G-CSF.  G-
CSF induces differentiation of 32D cells along the granulocytic pathway which was confirmed 
by the appearance of segmented neutrophils in wright-giemsa stained cytospins (data not shown).  
Western blot analysis (Fig. 4A) revealed that a four hour cytokine starvation (Ø) results in a 20% 
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 increase in p21 protein levels which dropped immediately following the G-CSF stimulus, 
decreasing by 50% by 3 days and thereafter.  p21 mRNA levels (Fig. 4B), experienced a similar 
acute reduction in expression, with a trough at 3 days, closely paralleling p21 protein levels 
during this period (Fig. 4C).  However, we observed that p21 mRNA levels increased after 3 
days, without a corresponding increase in p21 protein.  This parallels findings reported elsewhere 
for differentiating CD34+ cells 99,100. 
Because p21 protein has been reported to inhibit apoptosis when localized to the cytoplasm 
during monocytic differentiation, we examined the compartmental distribution of p21 during 
granulocyte differentiation 81.  In 32D cells maintained in the undifferentiated state with IL-3, we 
observed an equal cytoplasmic and nuclear distribution of p21 (Fig. 4D).  Transition to G-CSF 
revealed an almost complete shift to the cytoplasm, which was maintained through terminal 
differentiation.  We also observed an upregulation and predominant cytoplasmic localization of 
p27, a cip/kip family member closely related to p21. 
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Figure 4.  p21 expression decreases in G-CSF treated 32D cells. 
 
a) p21 protein levels decrease in differentiating 32D cells.  Cells propagating in IL-3 were 
cytokine starved, (Ø), and stimulated to differentiate with G-CSF.  Each lane contains 3x105 
viable cells harvested daily, prepared directly in laemmli buffer, which were subjected to SDS-
PAGE.  p21 levels were determined by immunoblot with β-actin provided as a loading control.  
b)  p21 message levels change during differentiation.  Total RNA prepared at each time point 
was probed by northern blot for p21 mRNA.  GAPDH signal is provided as a loading control.  c)  
p21 protein and p21 message are regulated independently during differentiation.  Quantification 
of signal density for p21 protein (1a) and mRNA (1b) was normalized against β-actin and 
GAPDH, respectively, and plotted.  d)  p21 shifts to cytoplasm during differentiation.  Nuclear 
and cytoplasmic extracts were prepared at each time point and subjected to SDS-PAGE and 
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 immunoblot analysis in sequence for p21, p27, with Lamin B1 and Tubulin provided as 
compartmentalization controls. 
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2.4.2. p21 suppresses 32D cell growth in IL-3 and G-CSF 
To determine if p21 regulates survival in 32D cells during differentiation, we first 
engineered 32D cells to overexpress a myc-his tagged human p21 transgene by retroviral 
transduction with MIG hp21WT or a control virus, MIG CTL.  We evaluated clonal cell lines by 
western blot and isolated two clones, clones 6 and 9, expressing comparable levels of the p21 
transgene (Fig. 5A).  First described as the downstream effector of p53-induced growth arrest 
28,29, p21 can inhibit the cell cycle through binding and inactivation of Cyclin E or Cyclin 
A/Cdk2 complexes.  It is thought that this occurs when p21 levels rise to sufficient levels to 
overcome sequestration by other binding partners (27 for review), most notably Cdk4/CyclinD 
complexes.  To determine if overexpression of p21 inhibited cell growth, we evaluated the 
expansion of cells propagating in IL-3 (Fig. 6B) or those stimulated with G-CSF (Fig. 6C).  
Whereas cell growth in IL-3 was modestly attenuated, cells treated with G-CSF underwent 
dramatic growth suppression compared to controls.  Consistent with a reduced growth rate, cell 
cycle analysis (Fig. 7D) revealed that p21 overexpression was correlated with a higher 
percentage of cells residing in the G1 phase during IL-3 stimulated expansion.  G-CSF treatment 
for 24 hours led not only to reduced S and G2/M phase populations, but a substantial increase in 
Sub-G1 populations in both p21 overexpressing clones compared to the control.  This result was 
consistent with increased apoptosis of p21 overexpressing clones in G-CSF.  
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Figure 5.  Exogenous p21 inhibits 32D cell growth in IL-3 and G-CSF. 
 
a)  32D cells were transduced with either a control virus (CTL) or virus carrying myc-his tagged, 
wild-type human p21 (clones 6 and 9).  Protein lysates were prepared from generated clones and 
were assessed for equivalent transgene expression and compared to control (CTL) and parental 
(32D) cells by immunoblot analysis using antibodies against p21.  β-actin signal is provided as a 
loading control.  b and c)  Exogenous p21 inhibits proliferation in IL-3 and G-CSF.  Cell 
numbers were determined by trypan blue dye assay and are presented as viable cells/ml cell 
suspension (*p<0.05; bars denote standard error of the mean). d) Cell cycle distribution of cells 
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 propagating in IL-3 or treated with G-CSF for 24 hours.  DNA content was assessed on the basis 
of propidium iodide uptake.  
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2.4.3. Exogenous p21 promotes apoptosis upon IL-3 withdrawal and during 32D cell 
differentiation with G-CSF.   
Between 10-20% of 32D cells switched from IL-3 to G-CSF undergo apoptosis within the 
first 24 hours.  Since p21 inhibits apoptosis during monocytic differentiation 81, we examined 
whether sustained expression with exogenous p21 could mitigate the observed differentiation-
induced apoptosis in a granulocytic model.  p21 increased apoptosis 2-fold after 2 days of G-CSF 
stimulation in clone 6 (35.3% +/-2.4% vs. 15.2% +/-3.6%, p<0.05), and increased apoptosis in 
clone 9 by 2-fold after 3 days (36.3% +/- 6.0% vs. 14.1% +/- 1.8%, p<0.05) (Fig. 3A).  To 
determine if the decrease in viability was correlated with caspase activation, we assayed total 
cellular protein for the 19 kDa cleavage product of Caspase-3 (Fig. 6B).  In both clones 6 and 9, 
caspase activation was markedly higher following G-CSF stimulation compared with control 
cells.  Activation was characterized by a signal peak after one day.  This was diminished after 48 
hours, presumably because of decreased p21 expression at day 2 (Fig. 6C).  To evaluate early 
events in apoptosis, we assessed Annexin V reactivity of cells treated with G-CSF.  At 24 hours, 
clone 6 exhibited a 4-fold increase in Annexin V binding when compared with the control 
population (24.51% +/- 4.48% vs. 6.06% +/- 0.62%, p<0.02) (Fig. 7). 
In order to determine whether G-CSF signals cooperated with p21 in promoting cell death 
or whether IL-3 deprivation enabled the p21 proapoptotic effect, we analyzed cell death at high 
and low IL-3 concentrations.  Cells were cultured in IL-3 at concentrations ranging from 1 ng/ml 
to 1 pg/ml and cell viability at 48 hours was determined (Fig. 6C).  At doses of 10 pg/ml both 
clones exhibited a ~1.5 fold decrease in viability relative to control (clone 6:  64.5% +/- 6.4%, 
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 p<0.03, clone 9:  57.8% +/- 3.0%, p<0.01, vs. control:  40.7% +/- 0.5%), with clone 6 showing a 
2-fold decrease in viability at 100 pg/ml (35.0% +/- 1.2% vs. 17.6% +/- 1.7%, p<0.01).  At 1 
pg/ml of IL-3, both control and p21 overexpressing clones experienced ~70% viability loss.  This 
indicates that accelerated cell death associated with p21 did not require G-CSF signaling, but 
rather loss of IL-3 signaling. 
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Figure 6.  Exogenous p21 is proapoptotic during 32D cell differentiation. 
 
a)  32D cells induced to differentiate with 100 ng/ml G-CSF were assessed for viability daily by 
trypan blue dye assay.  Data reported as change in viability from initial G-CSF stimulus at day 
zero.    b)  Exogenous p21 sensitizes 32D cells to IL-3 withdrawal.  IL-3 was titrated from 1 
ng/ml to 1 pg/ml and cells were assessed for viability by trypan blue dye assay.  Data presented 
for day 2, reported as change in viability from day zero ((a and b) *p<0.05; bars denote standard 
error of the mean).  c)  Exogenous p21 promotes activation of Caspase-3 during differentiation.  
1.5x105 cells from a) were harvested, prepared directly in laemmli buffer and subjected to SDS-
PAGE and immunoblot analysis.  Nitrocellulose membranes were probed in sequence with 
antibodies against cleaved Caspase-3, p21 and β-Actin.  (I = IL-3, G = G-CSF).   
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Figure 7.  Exogenous p21 increases apoptosis in G-CSF stimulated cells measured by Annexin-V labeling.   
Negative control cells (left column) and a representative p21 overexpressing clone (clone 6, right 
column) were analyzed by Annexin V-PE/Sytox Blue staining after a 24 hour stimulation with 
IL-3 (top row) or G-CSF (bottom row).  Table reports percent positive for G-CSF treated cells. 
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2.5. Discussion 
 
We tested the hypothesis that exogenous overexpression of p21 would suppress 
differentiation-associated apoptosis in 32D cells.  We demonstrate, in contrast, that 
overexpression of p21 promoted apoptosis within the first 48 hours of G-CSF stimulation (Figs. 
5D and 6A).  Apoptosis was manifested by increases in Caspase-3 cleavage and Annexin V 
reactivity (Figs. 6 and 7).  p21-mediated apoptosis occurred in two independent clones as well as 
in polyclonal culture (2-fold increase in apoptosis compared with control polyclonal culture, data 
not shown), indicating that it was not related to clonal selection.  These findings are significant 
because they suggest that p21 function in cell survival is distinct and opposite between 
granulocytes and monocytes.  
p21 has been previously described as an antiapoptotic protein in monocytic lineages, with 
upregulation occurring immediately following differentiation stimuli 81,101.  In monocytes, 
antiapoptotic effects depend on cytoplasmic localization of p21, where p21 binds to and inhibits 
ASK1 kinase81,261.  In contrast, proapoptotic effects of p21 occur despite its presence in the 
cytoplasm (Fig. 4D) and presumed accessibility to ASK1 in 32Dcl3 cells. 
p21 overexpression sensitizes 32D cells to cell death only upon IL-3 withdrawal.  This 
finding is distinct from other reports linking p21 overexpression to apoptosis.  In those systems 
exogenous p21 is sufficient to promote apoptosis or promotes apoptosis in conjunction with 
death receptor activation82,83, DNA damaging agents84,85, ionizing radiation86, or antioxidant 
treatments87-89.  Exogenous p21 alone has been sufficient to induce apoptosis in cervical90, 
esophageal91, and breast cancer cell lines92 and a peptide corresponding to the C-terminus of p21 
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 has recently been shown to cause apoptosis in the U937 cell line 93.  In our system p21 
overexpression was insufficient to cause apoptosis in proliferating cells.  IL-3 withdrawal or 
cytokine substitution with G-CSF was required to trigger apoptosis.  IL-3 withdrawal has been 
described to upregulate the secreted lipocalin 24p3, causing an autocrine induction of apoptosis 
which is insensitive to repletion of IL-3262.  Whereas exogenous lipocalin 24p3 is sufficient to 
trigger apoptosis in hematopoietic cells propagating in IL-3, 32Dcl3 cells supported by G-CSF 
are insensitive to lipocalin 24p3-mediated cell death263.  Because p21 promoted apoptosis in the 
setting of IL-3 withdrawal or in the presence of G-CSF, its mechanism of action is unlikely to 
involve lipocalin 24p3.  
Why would IL-3, and not G-CSF, suppress p21 augmented apoptosis?  Both IL-3 
withdrawal and substitution of G-CSF for IL-3 unmask proapoptotic effects of p21.  This could 
reflect either IL-3-specific modification of p21 to minimize its apoptotic potential or differences 
between IL-3 and G-CSF in the strengths or repertoire of survival signals they transmit.  Khanna 
et. al. have noted differences in p21 migration on 2-D gels in IC.DP premast cell derivatives 
cultured in the presence and absence of IL-3.  Phosphorylation of p21 on Thr-145 by AKT has 
been published 209,264, however both IL-3 and G-CSF have been reported to activate AKT in 32D 
cells 265,266.  Future work will characterize post-translational modification of p21 in 32D cells in 
IL-3 and G-CSF in order to map and validate p21 residues which are modified in association 
with apoptosis induction.  Differences in survival signaling between IL-3 and G-CSF 158,262,267,268 
also may account for differential suppression of p21-induced apoptosis. 
p21-induced apoptosis during differentiation has also been reported in muscle cells 
deficient in the Rb protein 269.  In this myotube differentiation model, Peschiaroli et. al. 
demonstrated that initiation of differentiation by MyoD is required for apoptosis to occur and 
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 that p21 knockout was protective.  The association of p21-mediated apoptosis with a 
differentiation trigger observed in muscle parallels our observations in the 32Dcl3 system. 
Promotion of apoptosis by p21 may be related to dysregulated Cdk function.  In the 
myogenesis system utilized by Peschiaroli, p21 expression and apoptosis coincided with nuclear 
redistribution of Cdk’s.  In an erythroblast differentiation model, Matushansky et. al. 
demonstrated that a specific order of Cdk inhibition was required to commit proerythroblasts to 
differentiate102,110.  Apoptosis occurred when this sequence of Cdk-inhibition was reversed.  
Based on these observations in muscle and erythroid differentiation systems, it is conceivable 
that an analogous system of precise temporal inhibition of Cdk’s and/or intracellular localization 
is required for both differentiation and survival in myeloid cells. 
In 32D cells, p21 levels decrease when cells are switched from IL-3 to G-CSF, whereas 
the levels of p27 increase (Fig. 4).  This parallels findings in muscle, where a successive spike in 
expression of distinct cyclin dependent kinase inhibitors (e.g., p21 peaking before p18) occurs 
upon transition to a more differentiated state and parallels sequential induction of p21 and p27 
which we have noted in a K562 myeloid model expressing inducible p2197,270,271.  p27 appears to 
play a primary role in terminal differentiation arrest in 32D cells 158.  Our results suggest that p21 
downmodulation enhances cell survival during the final stages of differentiation in which p27 
levels increase. 
In conclusion, we have detected a proapoptotic function of p21 in 32D cells which is 
unmasked by cytokine withdrawal of IL-3 or substitution of G-CSF for IL-3.  Our finding 
expands the number of examples in blood cells 83 and other cell systems in which p21 is 
proapoptotic 56.  Accumulated evidence tends to support a model wherein p21 is antiapoptotic 
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 when coupled to p53 signals and is proapoptotic with other death signals.    Our results indicated 
that p21 promotion of cell death can be cytokine specific in the absence of other death signals.  
Promotion of apoptosis by p21 at the myeloblast to myelocyte developmental transition 
may be a mechanism utilized to put a brake on myelopoiesis in response to acute changes in the 
cytokine environment.  It is conceivable that aberrant modulation of p21 could contribute to 
disease processes characterized by excessive apoptosis during the myeloblast to myelocyte 
transition such as that occurring in a subset of myelodysplastic syndromes.  
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3.1. Introduction 
 
Cellular differentiation is a complex process mediated by growth and developmental factors 
that requires precise control of gene expression.  Posttranscriptional regulation of mRNA is an 
important mechanism that modulates both rapid and long-acting responses to differentiation 
cues.  Recent work has demonstrated that neuronal and myogenic differentiation depends upon 
RNA-binding proteins that regulate mRNA turnover.  For example, induction of neurite 
outgrowth and regulation of cell fate in neural progenitor cells is dependent on the expression 
and RNA-binding activity of neuronal Hu proteins272,273.  In addition, during myogenesis, the 
RNA-binding proteins (RNA-BPs) HuR and NF90 mediate mRNA stabilization of the critical 
myogenic developmental factors myogenin, MyoD and the cyclin-dependent kinase inhibitor 
p21waf1/cip1 (p21) through interactions with AU-rich elements in their 3’ untranslated 
regions194,196.  Such transcript stabilization contributes to the steady rise in p21 expression during 
muscle and neuronal differentiation.  The binding of stabilizing or destabilizing RNA-BP's to 
common sequence elements in 3' UTR's facilitates coordinated expression of gene products 
beyond that achieved by transcription alone.  This control of multigene stability has been 
compared to "eukaryotic operons" and is critical in highly regulated processes such as 
differentiation274.  A result in muscle cells is an increase in transcription factor levels concurrent 
with a steady increase in p21 during differentiation.  
 p21 does not steadily increase during granulocytic differentiation95,99,100.  Our data 
indicates that p21 is posttranscriptionally regulated in this setting also. Posttranscriptional 
regulation of many genes, including c-Myc, neutrophil elastase and multiple cytokines, has also 
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 been demonstrated in leukemic cell lines induced to undergo myeloid differentiation275-278.  
However, neither the mechanisms that control mRNA stabilization during myelopoiesis nor the 
role of RNA-binding proteins in myelopoiesis are well understood. 
 Several recent reports have shown that control of p21 expression in response to cellular 
stress, growth factors, and differentiation stimuli occurs through posttranscriptional mRNA 
stabilization; however, how p21 is regulated during myeloid development remains unclear186-
191,193.  High basal levels of p21 expression can be found in the IL-3 dependent, myeloid 
progenitor cell line 32Dcl3(Figure 4 and 279).  p21 expression patterns in 32Dcl3 cells 
undergoing granulocytic differentiation in response to the cytokine G-CSF mirror those observed 
during granulocytic differentiation of CD34+ human hematopoietic progenitor cells(Figure 4 and 
100).  Therefore, 32Dcl3 cells provide an excellent model system to study p21 mRNA stability 
during myelopoiesis. 
IL-3 is responsible for maintenance of the undifferentiated state in 32Dcl3 cells and can 
promote the survival and proliferation of myeloid progenitors in vivo231-233.  IL-3 is often 
secreted by leukemic myeloblasts280,281 and can activate DNA synthesis and proliferation in  
primary AML cells, as well as support self-renewal by promoting growth of AML-colony 
forming cells249,250.  Although IL-3 can increase mRNA stability of its own receptor subunits in 
mature eosinophils256, investigations of posttranscriptional mechanisms elicited by IL-3 during 
differentiation, or in the setting of leukemic transformation, are limited. 
Conserved cis-acting sequences within an mRNA often serve as docking points for RNA-
binding proteins that regulate mRNA turnover.  p21 mRNA contains three AU-rich elements 
(AREs) in its proximal 3’ UTR that are specifically bound by stabilizing proteins including HuR 
and NF90, or destabilizing proteins such as AUF1194.  For example,  stabilization of p21 mRNA 
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 by Prostaglandin A2 has been shown to depend upon ERK-induced HuR binding to p21 AREs189.  
One mechanism recently reported suggests that steady-state levels of p21 mRNA result from 
competition between HuR and AUF1 for ARE binding184.  Competition for access to ARE sites 
between HuR and other destabilizing RNA-binding proteins such as TTP and KSRP has also 
been described and has been hypothesized to represent a general phenomenon regulating mRNA 
stability184,185.  In light of these studies, we hypothesized that competition between RNA-binding 
proteins may be a cytokine regulated phenomenon that controls p21 mRNA levels in 32Dcl3 
cells during differentiation. 
We report here that IL-3 maintains high levels of p21 expression in 32Dcl3 cells through 
stabilization of p21 mRNA requiring a functional 3’UTR region.  The decrease in p21 mRNA 
stability noted during G-CSF-induced differentiation was rescued by IL-3 and independent of 
PI3-kinase and ERK pathway signaling.  In vitro binding assays provide evidence that distinct 
sets of RNA:protein interactions occur within the p21 3’ UTR and are regulated by IL-3 and G-
CSF signaling.  These findings provide the first evidence for IL-3-mediated stabilization of 
mRNA transcripts in myeloid progenitor cells and suggest that IL-3 mediated mRNA 
stabilization may be an important mechanism that contributes to differentiation blockade. 
3.2. Materials and Methods 
 
3.2.1. Cells and Culture 
RPMI 1640 media supplemented with 10% fetal bovine serum, penicillin-streptomycin 
(100 I.U./ml and 100 ug/ml) and 2 mM L-Glutamine (Mediatech, Herndon, VA) was used to 
culture 32Dcl3 cells259 (kind gift from Alan Friedman, Johns Hopkins University).  Cells were 
maintained between 2x105 and 1x106 cells/ml with Murine IL-3 (Peprotech, Rocky Hill, NJ) 
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 used at 1.5 ng/ml during cell passaging.  All incubations were conducted at 37°C with 5% CO2.    
p21 transduced 32D cells, 32D hp21WT clone 6,  generated as described (see 2.3.1, (279), were 
cultured in IL-3 supplemented RPMI as above.  Cytokine independent v-Abl transduced 32D 
cells generated as described 282 were cultured in RPMI with fetal bovine serum, penicillin-
streptomycin and L-glutamine as noted above. 
 
3.2.2. Differentiation 
32Dcl3 cells were washed twice with 50 ml PBS to remove IL-3, resuspended in cytokine 
free media to 2x105 cells/mL and treated with 100 ng/mL G-CSF (Amgen, Thousand Oaks, CA) 
to trigger differentiation.  Partial media changes were executed every two days to maintain cell 
densities below 1x106 cells/mL and to replenish G-CSF.  Granulocytic differentiation was 
confirmed by analysis of Wright-Giemsa stained cytospins at each time point assessed (data not 
shown). 
 
3.2.3. Western Blotting 
 For differentiation analysis, whole cell protein extracts were prepared by direct lysis in 
sample buffer to minimize upregulated protease activity.  For each time point analyzed, 3.0x105 
viable cells, determined by trypan blue dye assay using a Vi-Cell XR cell viability analyzer 
(Beckman-Coulter, Miami, FL), were harvested, washed once in ice-cold PBS, lysed directly in 
15 µl 2X sample buffer (0.125 M Tris-HCl pH 6.8, 4% SDS, 20% Glycerol, 2% 2-
mercaptoethanol, 0.03 mM Bromphenol Blue), and boiled for 5 minutes.  p21 protein half-life 
determinations were performed using extracts prepared in modified RIPA buffer (50 mM Tris-
HCl pH 7.4, 150 mM NaCl, 0.25% Na-Deoxycholate, 1.0% NP-40, 1 mM EDTA, 1 mM PMSF, 
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 1 mM NaF, 0.5 mM DTT, 1.0 mM Vanadate, 1:250 Protease Inhibitor Cocktail (Sigma-
Aldrich)), quantified using a BCA protein assay (Pierce, Rockford, IL), and boiled as noted in 
2X sample buffer.  32D v-Abl cells at 1x106 cells/mL were treated with either 2 µM STI571 
(kind gift from Tom Smithgall, University of Pittsburgh) or DMSO as a vehicle control.  Cells 
were harvested at 0, 2 and 8 hour time points, washed in ice-cold PBS and protein extracts were 
prepared in modified RIPA buffer containing 50 nM Calyculin A (Cell Signaling Technology, 
Beverly, MA). 
Lysates containing equal amounts of total protein, or an equivalent number of whole cells 
lysed directly in 2x sample buffer, were separated using 12% SDS-PAGE.  Proteins were 
electrotransferred onto Protran membranes (Schleicher and Schuell, Keene, NH), which were 
incubated with Ponceau S (Sigma-Aldrich) to confirm transfer efficiency.  Membranes were then 
incubated with blocking buffer (5% w/v nonfat dry milk, 1x TBS, 0.1% Tween-20) for 1 hour.  
Primary antibodies were diluted in blocking buffer and included mouse monoclonal β-Actin 
(AC15) (1:20,000, Cat:  A5441 Sigma-Aldrich), rabbit polyclonal IgG Myeloperoxidase (1:3500, 
Cat:  91541, Assay Designs, Ann Arbor, MI),  goat polyclonal IgG TTP (1:200, Cat:  SC-8458, 
Santa Cruz), and  mouse monoclonal IgG1 DRBP76 (NF-90) (1:250, Cat: 612154, BD 
Transduction Laboratories, San Diego, CA).  Additional primary antibodies including goat 
polyclonal p21(C-19)-HRP (1:1000, Cat: SC-397HRP), goat polyclonal IgG Proteinase-3 (1:200, 
Cat:  SC-19748),  mouse monoclonal IgG1 HuR (3A2) (1:500, Cat:  SC-5261), rabbit polyclonal 
IgG hnRNP A/B (1:200, Cat:  SC-15385), and rabbit polyclonal IgG hnRNP K (H-300) (1:200, 
Cat:  SC-25373) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).  Membranes 
probed with mouse monoclonal IgG2bκ anti-phosphotyrosine (4G10 clone, 1:500, Cat: 05-321, 
Upstate Biotechnology, Lake Placid, NY) antibodies were blocked and probed using BSA buffer 
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 (5% w/v BSA, 1x TBS, 0.1% Tween-20).  All rabbit polyclonal IgGs including Akt (1:1000, Cat:  
9272), phospho-Akt (Thr308) (1:1000, Cat: 9275), p44/42 MAP kinase (1:1000, Cat:  9102), and 
phospho-p44/p42 MAP kinase (Thr202/Tyr204) (1:1000, Cat:  9101) obtained from Cell 
Signaling Technology were utilized per manufacturer’s instructions.  Where appropriate, 
secondary HRP-conjugated antibodies were diluted in blocking buffer and included goat anti-
mouse IgG (H + L)-HRP (Cat:  170-6516, Bio-Rad, Hercules, CA), goat anti-rabbit IgG (H + L)-
HRP (Cat:  170-6515, Bio-Rad) and donkey anti-goat IgG HRP (Cat:  SC-2033, Santa Cruz).  
Signals were developed using the Western Lightning chemiluminescence reagent (PerkinElmer, 
Boston, MA).  Scanned images of exposed film underwent signal density analysis using Image J 
1.31v software (http://rsb.info.nih.gov/ij). 
 
3.2.4. Half-life determination 
3.2.4.1. Protein 
 
Log phase 32Dcl3 cells cultured in IL-3 were washed with 50 mL PBS and resuspended to 
1x106 cells/mL in cytokine free media.  Cycloheximide (Sigma-Aldrich) was titrated to 10 
µg/mL, cell suspensions were divided into equal volumes and IL-3 was titrated to either 1 ng/mL 
or 10 pg/mL.  Cells were further treated with either 12.5 µg/mL MG132 (Sigma-Aldrich) or 
DMSO as a vehicle control and were harvested at 0, 1, 2, 3, 4 and 6 hour time points.  Harvested 
cells were washed once in ice cold PBS, snap-frozen in a dry ice/ethanol bath, and lysates 
prepared with modified RIPA buffer.  For half-life assessments made in G-CSF, cells were 
washed twice with 50 mL PBS and resuspended to 1x106 cells/mL in cytokine free media, G-
CSF was titrated to 100 ng/mL and cells were incubated for 18 hours to initiate the granulocytic 
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 differentiation program.  Cells stimulated with G-CSF for 18 hours were treated with 
cycloheximide or DMSO and harvested as above for the indicated time points. 
3.2.4.2. RNA 
 
32Dcl3 cells or 32D hp21WT cl6 cells were washed and resuspended as noted above.    
Actinomycin-D (Sigma-Aldrich) was titrated to 10 µg/mL and the culture was divided into two 
equal parts.  IL-3 was titrated to either 1 ng/mL or 10 pg/mL and RNA was prepared from 1x107 
cells at 0, 2, 4, and 6 hour time points using RNeasy total RNA purification kits (Qiagen, 
Valencia, CA).  For half-life assessments made in G-CSF, cells were prepared as noted above 
and incubated for 18 hours.  Actinomycin-D was titrated to 10 µg/mL and cell cultures were 
divided into two equal parts.  Cells received either 1 ng/mL IL-3 or an equal volume of water as 
a control.  RNA was prepared from cells harvested at 0, 2, 4 and 6 hour time points.  Where 
indicated, cells were treated with 50 µM LY294002 (Cell Signaling Technology) or an equal 
volume of DMSO as a vehicle control and incubated for 30 minutes prior to addition of 
Actinomycin-D.  Similarly, following G-CSF stimulation, cells were treated with 20 µM U0126 
(Cell Signaling Technology) or DMSO for 2 hours prior to addition of Actinomycin-D.  32D v-
Abl cells at 1x106 cells/mL were treated with either 2 µM STI571 or DMSO as a vehicle control 
and incubated for 2 hours.  Actinomycin-D was titrated to 10 µg/mL and cells were harvested at 
0, 1, 2, 4 and 6 hour time points.  Northern blotting for all experiments was performed as 
described in section 2.3.7.  Signal density analysis of scanned images was performed using 
Image J 1.31v software (http://rsb.info.nih.gov/ij).  Multiple exposures were obtained to optimize 
linearity of signal. 
 
3.2.5. Nuclear/Cytoplasmic fractionation 
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 Cells treated with IL-3 and/or G-CSF as described above were harvested for preparation of 
nuclear and cytoplasmic protein extracts.  Pelleted cells were washed with 1 mL of ice-cold PBS, 
treated with cytoplasmic extraction buffer (10 mM HEPES pH 7.9, 14 mM KCl, 3 mM MgCl2, 
5% glycerol, 0.2% NP-40, 10 mM NaF, 1.0 mM DTT, 1.0 mM Vanadate, 50 nM Calyculin A, 
1.0 mM Pefabloc, 2% CLAP cocktail – (20 µg/ml each chymostatin, leupeptin, antipapain, and 
pepstatin A)), mixed by pipetting 10-15 times and incubated on ice for 20 minutes.  Intact nuclei 
were verified by microscopic examination in the presence of trypan blue dye.  Nuclei were 
pelleted at 3000 RPM for 3 minutes at 4 C° (Heraeus 7500 3325 rotor) and cytoplasmic 
supernatants were transferred to pre-chilled tubes and snap-frozen in a dry ice/ethanol bath.  
Nuclei were washed once with cytoplasmic extraction buffer and pelleted as above.  Pellets were 
resuspended by pipetting in nuclear extraction buffer (20 mM HEPES pH 7.9, 420 mM NaCl, 20 
mM NaF, 1 mM Na4P2O7, 1 mM EDTA, 1 mM EGTA, 20% Glycerol, 1.0 mM DTT, 1.0 mM 
Vanadate, 50 nM Calyculin A, 2% CLAP cocktail, 1.0 mM Pefabloc) and subjected to three 
cycles of freezing and thawing on dry ice and wet ice, respectively.  Insoluble material was 
pelleted at 13,000 RPM for 30 minutes and supernatants were transferred to pre-chilled tubes and 
snap-frozen. 
 
3.2.6. Riboprobes 
T7 recognition-sequence containing PCR products of the murine p21 3’ untranslated region 
(Accession:  NM_007669) were amplified from phRL-p21 3’utr-FL (kind gift from Hirotaka 
Okano, Keio University195).    Gel purified amplicons were used as templates to synthesize [α-
32P]-UTP (Perkin Elmer, Boston, MA) labeled riboprobes in vitro using the Maxi-Script kit with 
T7 polymerase (Cat:  1312, Ambion, Houston, TX).  Biotinylated RNA probes synthesized in 
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 vitro were end-labeled by T4 polynucleotide kinase (New England Biolabs, Beverly, MA) using 
[γ-32P]-ATP.  The biotinylated probe sequence, h/m 37, was: 
TGTGTGTCTTAATTATTATTTGTGTTTTAATTTAAA.  Riboprobes were separated from 
unincorporated nucleotides using NucAway Spin Columns (Cat:  10070, Ambion) per the 
manufacturer’s instructions.  Riboprobes without radioactive label were synthesized as above 
using 0.5 mM UTP. 
 
3.2.7. Northwestern Blotting 
Nitrocellulose membranes containing transferred proteins, as described above, were 
incubated in northwestern buffer 194 (10 mM Tris-HCl pH 7.4, 150 mM KCl, 5 mM MgCl2, 
0.1% gelatin, 0.1% Tween-20, 50 µg/ml salmon sperm DNA) for 16 hours at room temperature.  
A 32P labeled T7-RNA probe (5x106 CPM/mL) containing nucleotides 580-1905 of the murine 
p21 3’UTR (Accession:  NM_007669) was hybridized to the membrane in northwestern buffer 
with 50 µg/mL yeast tRNA for 2 hours at room temperature.  The membrane was washed in 
northwestern buffer twice for 5 minutes at room temperature and once for 2 hours at 45° C.  
Dried membranes were subjected to autoradiography. 
   
3.2.8. UV Crosslinking Assay 
Cytoplasmic extracts derived from cytokine treated cells were used in UV Crosslinking 
assays performed as described with modification283.  30 µg of protein extract was equilibrated in 
RNA binding buffer on ice for 20 minutes, T7-riboprobes (1x105 CPM/reaction) were added, and 
the reactions incubated for an additional 25 minutes on ice.  Reaction mixtures maintained on ice 
were exposed to UV light (254-nm) at a distance of 3 cm from the source for 16 minutes in a UV 
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 Stratalinker™ 1800 (Stratagene, La Jolla, CA).  RNase T1 (5 U/reaction, Ambion) and Heparin 
sulfate (30 µg/reaction, Sigma-Aldrich) were added and reactions were incubated at room 
temperature for 10 minutes.  RNase A (Sigma-Aldrich) was titrated to 30 µg/ml and mixtures 
were incubated for 10 minutes at 37° C.  An equal volume of 2X sample loading buffer was 
added and samples were boiled for 5 minutes.  Samples were separated by 8% SDS-PAGE.  
Dried gels were subjected to autoradiography. 
 
3.2.9. Statistics 
Protein and RNA half-life determinations were compared for all conditions tested with 
significance assessed by a 2-tailed, type 2 student’s t-test using 95% confidence intervals.  All 
calculations were made using the Excel software package (Microsoft, Redmond, WA). 
 
3.3. Results 
 
3.3.1. p21 protein stability is independent of IL-3 or G-CSF stimulation in 32Dcl3 cells. 
The myeloid progenitor cell line 32Dcl3 is a good model system for studying cytokine 
controlled mechanisms that regulate p21 gene expression during myeloid differentiation.  32Dcl3 
cells are dependent upon IL-3 for propagation, survival and maintenance of an undifferentiated, 
myeloblast state.  Withdrawal of IL-3 and treatment with G-CSF stimulates them to differentiate 
along the granulocytic pathway and leads to the formation of terminally differentiated 
neutrophils.  To validate the competence of this cell line to initiate granulocytic differentiation 
and establish p21 protein expression kinetics during this period, we treated 32Dcl3 cells with G-
CSF for 3 days.  Primary granule protein expression is the molecular hallmark of early 
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 granulocytic differentiation284.  Western blot analysis revealed that two primary granule proteins, 
myeloperoxidase and proteinase-3, are strongly upregulated within 48 hours following G-CSF 
stimulation (Fig 8A).  We next examined the effect of IL-3 and G-CSF on endogenous p21 
protein levels in 32Dcl3 cells.  Whereas basal levels of p21 protein were high in cells 
proliferating in IL-3, a rapid decrease is observed following stimulation with G-CSF, decreasing 
by 70% within 48 hours (Fig 8A).  This pattern of p21 protein expression mirrors the changes in 
p21 expression noted by our laboratory during cytokine-induced neutrophil differentiation of 
human CD34+ umbilical cord stem cells99,100. 
p21 protein half-life has been reported to be controlled by several stimuli including insulin, 
TGF-β, and ionizing radiation, but has not been studied in myeloid cells during 
differentiation210,215,230.  To determine if the observed decrease in p21 protein levels occurred due 
to changes in protein stability, we assessed whether changes in p21 protein half-life were a 
function of IL-3 concentration or occurred when G-CSF was substituted for IL-3.  32Dcl3 cells 
were treated with high or low levels of IL-3, or treated with G-CSF, and subjected to a 
cycloheximide chase analysis(Fig 8B, C).  Under all three conditions, there was no significant 
difference in p21 protein levels at each time point evaluated with protein half-life ~3.5 hours (t1/2 
3.6 hrs vs. 3.1 hrs vs. 3.4 hrs (high IL-3 vs. low IL-3 vs. G-CSF), (p>0.05, n = 3)).  These 
findings suggest that p21 protein stability in 32Dcl3 cells is not a function of IL-3 concentration 
or a destabilizing effect of G-CSF.  p21 protein levels were enhanced by coincubation with the 
proteasome inhibitor MG132 either in high or low IL-3 (Fig 8B).  This suggests that p21 protein 
is actively metabolized by the proteasome independently of the presence of IL-3. 
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Figure 8.  p21 protein stability is constant during differentiation. 
a)  p21 protein levels decrease during differentiation of 32Dcl3 cells.  Cells propagating in 1 
ng/mL IL-3 were washed and stimulated to differentiate with 100 ng/mL G-CSF.  Each lane 
contains 3x105 viable cells that were harvested daily and boiled directly in laemmli buffer.  
Samples were subjected to SDS-PAGE and immunoblot analysis with p21, myeloperoxidase 
(MPO) and proteinase-3 (PR3) antibodies.  β-actin is provided as a loading control.  b)  p21 
cycloheximide chase analysis in 32Dcl3 cells.  32Dcl3 cells were washed and treated with high 
or low doses of IL-3 (1 ng/mL vs. 10 pg/mL), with or without the proteasomal inhibitor MG132 
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 (15 µg/mL), and 10 µg/mL cycloheximide.  Total protein was extracted at 1, 2, 3, 4 and 6 hours 
after cycloheximide treatment and analyzed by immunoblotting.  Washed 32Dcl3 cells were 
incubated with G-CSF (100 ng/mL) for 18 hours and then treated with 10 µg/mL cycloheximide.  
Whole cell extracts were prepared in modified RIPA buffer and analyzed by SDS-PAGE and 
immunoblot with p21 and β-actin antibodies.  c)  Results in b) were subjected to signal density 
analysis using NIH Image 1.31v.  p21 values were normalized against β-actin and plotted.  Error 
bars denote standard error of the mean (n=3).  
83 
  
3.3.2. IL-3 stabilizes p21 mRNA 
Because p21 levels can be regulated either by changes in mRNA stability or changes in 
translation or transcription, we next examined the effect of IL-3 and G-CSF induced 
differentiation upon endogenous p21 mRNA expression levels in 32Dcl3 cells.  Withdrawal of 
IL-3 and transition of 32Dcl3 cells to G-CSF was accompanied by a 65% decrease in p21 RNA 
expression within 24 hours that remained depressed up to 72 hours (Fig. 9A).  To determine if 
this effect occurred at the posttranscriptional level and was simply a function of IL-3 withdrawal, 
we assessed p21 mRNA half-life by actinomycin-D chase analysis using high and low 
concentrations of IL-3 (Fig. 9B).  Because 32Dcl3 cells are dependent upon IL-3 for survival, we 
utilized low doses of IL-3, rather than the absence of IL-3, to prevent the activation of apoptotic 
cascades during the experimental time period.   By using low levels of IL-3 that were insufficient 
for ongoing expansion of cells, we maintained cell viability above (90%) throughout the duration 
of the experiment.   Densitometric analysis revealed a significant difference in p21 mRNA levels 
at all time points tested with a ~3.5-fold difference in half-life between high and low IL-3 
concentrations (3.7 vs. 0.95 hours, p<0.01) (Fig 9D).  This data supports the hypothesis that IL-3 
signals are required for stabilization of p21 mRNA in 32Dcl3 cells.  We next sought to determine 
if IL-3 signals could stabilize p21 mRNA in the presence of differentiation signaling by G-CSF.  
We first treated 32Dcl3 cells with G-CSF for 18 hours to initiate the granulocytic differentiation 
program.  Following actinomycin-D treatment, we observed a rapid decrease in p21 mRNA 
levels in these cells, and noted the p21 mRNA half-life was similar to that observed for cells 
exposed to low levels of IL-3 (1.0 vs. 0.95 hours, G-CSF vs. Low IL-3) (Fig 9B & C).  Addition 
of IL-3 to these differentiating cells significantly increased the half-life to 3.3 hours (1.0 vs. 3.3 
84 
 hours, G-CSF vs. G-CSF + IL-3, p<0.03) (Fig 9E).  Together these finding support stabilization 
of p21 message by IL-3 rather than destabilization by G-CSF.  
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Figure 9.  IL-3 stabilizes p21 mRNA. 
A)  Northern blot analysis of total RNA from 32Dcl3 cells propagating in IL-3 (1 ng/mL) or 
following treatment with G-CSF (100 ng/mL).  RNA harvested daily was probed with 32P-
labeled murine p21 cDNA.  Ethidium bromide stained 18S RNA is provided as a loading control.  
B)  p21 stability is a function of IL-3 concentration.  32Dcl3 cells were treated with 10 µg/mL 
actinomycin-D and either 1 ng/mL (Hi IL-3) or 10 pg/mL (Lo IL-3) murine IL-3.  Total RNA 
was extracted at 0, 2, 4 and 6 hours following actinomycin-D treatment and assessed by northern 
blot with 32P-labelled p21 and GAPDH probes.  C)  IL-3 stabilizes p21 mRNA in the presence of 
G-CSF.  32Dcl3 cells were incubated with 100 ng/mL G-CSF for 18 hours, treated with 10 
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 µg/mL actinomycin-D and either water (0.01%) as a vehicle control (G-CSF) or 1 ng/mL murine 
IL-3.  Total RNA was harvested and analyzed as in B).  D & E)  Quantification of 
autoradiograms depicted in B) and C) were performed by NIH Image 1.31v.  p21 signals 
normalized against GAPDH are plotted (*, p<0.05) with p21 mRNA half-life (hours) tabulated.  
Error bars denote standard error of the mean (n = 3). 
. 
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3.3.3. Stabilization of p21 mRNA by IL-3 is independent of the PI3-kinase and ERK 
pathways 
The hematopoietic cytokines M-CSF, GM-CSF and IL-3 have been reported to stimulate p21 
expression in macrophages through the PI3-kinase pathway285.  It has previously been reported 
that activation of this pathway by IL-3 is rapid and responsible for survival signaling in 32Dcl3 
cells265.  We wanted to determine if this pathway was activated by IL-3 in the setting of ongoing 
G-CSF signaling in our system.  Phosphorylation of Akt, a downstream target of PI3-kinase, was 
evident within 15 minutes of IL-3 stimulation (Fig. 10A), indicating that IL-3 was sufficient to 
rapidly activate the PI-3 kinase pathway.  Next, we sought to determine if PI3-kinase activity 
was required for the IL-3 mediated increase in p21 mRNA stability.  To facilitate this analysis, 
we employed the PI3-kinase inhibitor LY294002 and found that it could effectively reduce IL-3 
stimulated Akt phosphorylation at a dose of 50 µM (Fig. 10A, lanes 7-9).  Importantly, a 30 
minute treatment with this compound alone did not alter steady-state levels of p21 mRNA (Fig. 
10B, lanes 10 vs. 11).  p21 mRNA half-life was unchanged in cells treated with G-CSF and 
either LY294002 or a vehicle control (Fig 10B, lanes 1-5 vs. 11-15).  Upon IL-3 stimulation, a 
2.5 fold increase in half-life was observed in both LY294002 and vehicle treated cells (Fig 10B, 
lanes 6-9 vs. 16-19), indicating that stabilization of p21 mRNA by IL-3 signal pathways does not 
require PI3-kinase activity in 32Dcl3 cells. 
 ERK activity has been shown to regulate mRNA stability of several genes including, 
TGF-β, Cox-2 and the p21 relative p27kip1 286-288.  A recent report noted that Prostagladin-A2 
induced stabilization of p21 mRNA in the H1299 lung carcinoma cell line required ERK 
activation189.  ERK inhibition blocked stabilization by preventing HuR binding to the p21 
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 3’UTR.  Since the ERK pathway is activated downstream of IL-3 receptor ligation289,290, we next 
sought to determine if this pathway was mediating p21 mRNA stabilization by IL-3 during 
differentiation.  Western blot analysis was used to first verify that IL-3 could activate the ERK 
pathway in G-CSF treated 32Dcl3 cells.  Activation of ERK requires phosphorylation upon 
specific threonine and tyrosine residues which can be detected by phospho-specific antibodies.  
We noted a sustained ERK phosphorylation that was detectable within 15 minutes of IL-3 
treatment (Fig. 11A).  Optimal blockade of ERK activation was executed using 20 µM U0126, 
an inhibitor of the activating ERK kinase, MEK (Fig 11A).  p21 mRNA half-life was unchanged 
in G-CSF treated cells stimulated with IL-3 in the presence and absence of U0126 (t1/2 3.0 vs. 3.2 
hours, DMSO vs. U0126) (Fig 11B & C), suggesting that ERK pathway activation is not 
required for IL-3 mediated stabilization of p21 mRNA.        
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Figure 10.  IL-3 stabilization of p21 mRNA is independent of PI3-kinase activity 
 
A)  IL-3 activates the PI3-kinase pathway.  32Dcl3 cells were incubated with G-CSF for 18 
hours, treated for 30 minutes with 50 µM LY294002 or 0.01% DMSO as a vehicle control and 
then stimulated with 1 ng/mL IL-3.  Western blot analysis was conducted on whole cell protein 
extracts (15 µg/lane) prepared from cells harvested at the indicated time points (minutes) to 
detect phosphorylated Akt (p-Akt).  Equal loading was verified by detection of total Akt levels.  
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 B)  Northern blot analysis of p21 mRNA expression.  32Dcl3 cells incubated with G-CSF for 18 
hours were pretreated with DMSO or LY294002 as in A).  Actinomycin D was titrated to 10 
µg/mL and cells were treated with either 1 ng/mL murine IL-3 (G + I) or water as a vehicle 
control (G).  Total RNA was harvested at the indicated time points and probed with 32P-labeled 
murine p21 and GAPDH cDNAs.  C)  Densitometric analysis of autoradiograms depicted in B) 
with p21 signals normalized to GAPDH density.  p21 mRNA half-life is tabulated (hours).  
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Figure 11.  IL-3 stabilization of p21 mRNA is independent of MEK activity 
A)  IL-3 activates the ERK pathway.  32Dcl3 cells were incubated with G-CSF for 18 hours, 
treated for 2 hours with 20 µM U0126 or 0.01% DMSO as a vehicle control and then stimulated 
with 1 ng/mL IL-3.  Western blot analysis was conducted on whole cell protein extracts (15 
µg/lane) prepared from cells harvested at the indicated time points (minutes) to detect 
phosphorylated ERK (p-ERK).  Equal loading was verified by detection of total ERK levels.  B)  
Northern blot analysis of p21 mRNA expression.  32Dcl3 cells incubated with G-CSF for 18 
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 hours were pretreated with DMSO or U0126 as in A).  Actinomycin D was titrated to 10 µg/mL 
and cells were treated with 1 ng/mL murine IL-3.  Total RNA was harvested at 0, 1, 2 and 4 
hours and subjected to northern blot analysis with a 32P-labeled murine p21 cDNA probe.  
Ethidium bromide stained 18S RNA is provided to demonstrate equal loading.  C)  
Densitometric analysis of panels in B) with p21 signals normalized to 18S RNA density are 
plotted.  p21 mRNA half-life is tabulated (hours). 
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3.3.4. IL-3 stabilization of p21 mRNA requires the 5’ or 3’ untranslated regions 
 Cis-acting elements within the p21 3’UTR are required for p21 mRNA stabilization in 
several experimental systems189,191,193,196.  It is plausible that cis-elements within the p21 mRNA 
untranslated regions are necessary for IL-3 mediated stabilization in 32Dcl3 cells.  To test this 
hypothesis, we utilized 32D cells expressing a p21 transgene lacking either the 5’ or 3’ UTR (see 
Fig. 5A) 279.  Using the endogenous p21 transcript as an internal control, we examined p21 
mRNA half-life in response to high or low IL-3 levels.  We found that half-life of p21 transcripts 
devoid of UTR sequences was independent of IL-3 concentration (6.1 vs. 4.5 hours, high vs. low 
IL-3) (Fig 12 A & B).  Endogenous p21 transcripts recapitulated the ~3.5 fold difference in half-
life demonstrated in parental 32Dcl3 cells (3.2 vs. 0.9 hours, high vs. low IL-3).  This data 
suggests that regulatory elements reside in either the 5’ or 3’ UTR of p21 and are required for 
stabilization of p21 mRNA by IL-3.    
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Figure 12.  p21 mRNA stabilization by IL-3 requires the 3’UTR. 
A)  Northern blot analysis of p21 mRNA expression.  32D hp21WT cl6 cells were washed, 
treated with 10 µg/mL Actinomycin-D, and stimulated with 1 ng/mL IL-3 (Hi IL-3) or 10 pg/mL 
IL-3 (Lo IL-3).  Total RNA was harvested at 0, 2, 4 and 6 hours and subjected to northern blot 
analysis with 32P-labeled p21 and GAPDH probes.  C)  Densitometric analysis of autoradiograms 
in A) with p21 signals normalized to GAPDH density is plotted.  p21 mRNA half-life is 
tabulated (hours). 
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Figure 13.  Schematic representation of the murine p21 mRNA and RNA probes. 
Schematic representation of the murine p21 mRNA (nt 1-1909, Genbank Accession # 
NM_007669) with coding region denoted in gray and conserved AU-rich elements (AREs) 
represented by blue squares.  In vitro transcribed RNA probes used in this study are depicted. 
 
3.3.5. IL-3 stimulated p21 mRNA binding proteins localize to the cytoplasm 
 To determine whether RNA binding proteins in 32Dcl3 cells are capable of binding the 
p21 3’UTR under various cytokine conditions we utilized northwestern blotting and UV 
crosslinking assays.  Two RNA probes were used in these studies:  p21 3’ FL, which contained 
the full length murine 3’UTR sequence (nt 580-1905), and p21 3’ 883, which contained the 
proximal 303 nucleotides, including the three AU-rich elements that are conserved between 
human, mouse and rat species.  Northwestern blot analysis with the p21 3’ FL probe labeled a 
prominent 90 kDa interacting protein in whole cell extracts from 32Dcl3 treated with either IL-3 
or G-CSF (Fig 14A).  Because the fate of p21 mRNA can be determined by interactions with 
cytoplasmic RNA-binding proteins such as HuR and AUF1184, we determined the subcellular 
distribution of this 90 kDa RNA binding protein and whether its compartmentalization changed 
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 as a function of IL-3 or G-CSF exposure. Although an RNA-binding activity was not observed in 
cytoplasmic extracts, a similar 90 kDa protein was labeled by the p21 3’FL probe in nuclear 
extracts (Fig. 14B).  This signal did not vary with changes in IL-3 dose or in response to G-CSF 
stimulation.  To evaluate the possibility that the absence of binding in cytoplasmic extracts was 
due to insufficient protein loading (15 µg/lane), we probed membranes containing 80 µg of 
cytoplasmic extract per lane (loading used in Fig 14A).  No detectable labeling of proteins was 
observed under these conditions (data not shown).  These results demonstrate an RNA-binding 
activity in 32Dcl3 cells and identify a 90 kDa nuclear protein that is capable of binding the p21 
3’UTR.
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Figure 14.  RNA-binding proteins in 32Dcl3 cells interact with the p21 3’UTR. 
A)  Northwestern blot analysis of whole cell protein extracts (80 µg/lane) from 32Dcl3 cells 
treated with either 1 ng/mL IL-3 or 100 ng/mL G-CSF for 18 hours.  Proteins were separated by 
SDS-PAGE and transferred to nitrocellulose membranes.  Membranes were probed with in vitro 
transcribed 32P-labeled p21 3’FL riboprobes and signals determined by autoradiography.  B)  
Northwestern blot of nuclear and cytoplasmic extracts (15 µg/lane) derived from 32Dcl3 cells 
treated with cytokines as follows:  10 pg/mL IL-3 (Lo IL-3) or 1 ng/mL IL-3 (Hi IL-3) for 6 
hours, 100 ng/mL G-CSF for 24 hours (G-CSF), and 100 ng/mL G-CSF for 18 hours with 1 
ng/mL IL-3 for an additional 6 hours (G + I).  Membranes were prepared and probed as noted in 
A).   
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  To characterize other potential cytokine responsive p21 mRNA binding proteins, UV 
crosslinking (UVXL) assays were utilized.  UVXL assays provide high sensitivity resolution of 
RNA-protein interactions, including those that may be transient in nature or of low affinity, such 
as those found in the cytoplasm283.  Both the p21 3’FL and p21 3’883 riboprobes were used to 
identify ARE binding proteins whose binding activity may be modulated during differentiation.  
Cytoplasmic extracts derived from cells treated with IL-3 or G-CSF for 18 hours were examined.  
Several proteins were found to interact with the p21 3’FL and p21 3’883 probes (Fig. 15A).  
Although binding to both riboprobes by the majority of proteins was independent of cytokine 
stimulation, RNA-protein complex formation was differentially regulated by IL-3 and G-CSF for 
two proteins (Fig 15A, arrows).  An RNA-protein complex of ~60-65 kDa apparent mass was 
noted in IL-3 extracts, but absent in G-CSF extracts.  Conversely, an RNA-protein complex of 
~40-42 kDa apparent mass was found in G-CSF extracts, but was absent in IL-3 extracts.  This 
pattern was observed for both riboprobes, suggesting that these RNA-protein complexes are 
localizing to the proximal 303 nucleotides of the p21 3’UTR.  Analysis of several known RNA-
binding proteins, including those previously reported to bind p21 mRNA, by western blot 
revealed an exclusively nuclear localization for NF90, hnRNP K, HuR, TTP, and hnRNP A/B 
with no detectable changes in subcellular localization in response to G-CSF or IL-3 stimulation 
(Fig 16).  However, AUF1 was found to localize in both the nucleus and cytoplasm.  Multiple 
AUF1 isoforms were detected, with a small percentage of total AUF1 found in cytoplasmic 
extracts, present at an apparent mass of ~40-42 kDa(Fig. 16). 
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Figure 15.  Cytoplasmic p21 mRNA-binding proteins are differentially regulated by IL-3 and G-CSF. 
A)  UV crosslinking analysis of p21 3’UTR binding proteins.  Extracts from IL-3 or G-CSF 
treated 32Dcl3 cells, or from unstimulated 32Dcl3 v-Abl, were incubated with either 32P-labeled 
p21 3’FL or p21 3’883 riboprobes, crosslinked by UV exposure and separated by 8% SDS-
PAGE.  Dried gels were analyzed by autoradiography.  Labeled riboprobe RNA in the absence 
of 32Dcl3 extracts was included as a control (Probe).  Migration of prestained molecular mass 
markers is indicated (kDa).  Arrows denote proteins with binding changes between IL-3 and G-
CSF.  Arrowhead denotes a protein unique to v-Abl transduced cells.  B)  Known RNA-binding 
proteins with their respective molecular masses are tabulated (*masses of known isoforms 
indicated).    
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Figure 16.  Compartmental distribution of RNA-binding proteins is unchanged during differentiation. 
Cytoplasmic (C) and nuclear (N) extracts (15 µg/lane) were separated by SDS-PAGE and 
immunoblotted in sequence with antibodies directed against NF90, AUF1, hnRNP K, HuR, 
hnRNP A/B and TTP.  Ponceau S staining of nitrocellulose membranes is shown as a loading 
control. 
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3.3.6. p21 mRNA half-life is independent of v-Abl kinase activity 
High levels of p21 expression were noted in the 32Dcl3 v-Abl cell line (Fig 17A).  These cells 
were transduced with the v-Abl oncogene, do not require cytokines for survival, and are resistant 
to differentiation signals provided by G-CSF95.  We utilized these cells to determine if RNA-
protein complexes associated with IL-3 stabilized p21 mRNA were recapitulated in cytokine 
independent cells that have been transformed by a nonreceptor tyrosine kinase associated with 
leukemia.  Comparison of p21 RNA-protein complexes from 32Dcl3 v-Abl cell extracts with 
those from IL-3 treated cells demonstrated a similar set of interactions with both the p21 3’UTR 
and p21 3’883 riboprobes.  One RNA-protein complex of ~42-48 apparent mass was unique to 
32Dcl3 v-Abl extracts, and also absent in G-CSF treated cells (Fig 15A, arrowhead).  These 
findings suggest that IL-3 independent p21 RNA-binding activity is present in 32Dcl3 v-Abl 
cells and includes a distinct RNA-protein complex. 
 Since p21 mRNA-protein complexes were present in 32Dcl3 v-Abl cells, we sought to 
determine if v-Abl kinase activity was required for stabilization of the p21 transcript.  To 
accomplish this we employed the tyrosine kinase inhibitor STI-571, a compound with high 
specificity for the Abl kinase domain.  Effective kinase inhibitory concentrations for this 
compound have been reported to range from 1-4 µM in vitro and in vivo291.  We found that a 2 
µM dose of STI-571 decreased total cellular tyrosine phosphorylation within 2 hours and did not 
impact cell viability (Fig. 17A and data not shown).  While p21 protein expression was reduced 
within 2 hours of treatment with STI-571 (Fig. 17A), this compound did not alter p21 transcript 
half-life as determined by actinomycin chase analysis (Fig. 17 B & C).  Evaluation of p21 
protein stability in 32Dcl3 v-Abl cells demonstrated that p21 protein half-life was independent of 
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 v-Abl kinase activity (data not shown).  Taken together, these results suggest that v-Abl kinase 
activity may be promoting p21 expression at the level of transcription or translation.    We 
therefore determined whether the decrease in p21 protein seen in STI-571 cells still occurred in 
the presence of the transcriptional inhibitor Actinomycin D.  p21 protein levels were decreased 
by STI-571 whether transcription was blocked or not (data not shown).  In aggregate, these 
results suggest that v-Abl may be enhancing p21 translation, as Bcr-Abl has been reported to do 
for the C-Myc and MDM2 genes292. 
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Figure 17.  p21 mRNA half-life does not depend upon v-Abl kinase activity. 
A)  p21 protein expression decreases following v-Abl inhibition.  Western blot analysis of 
32Dcl3 v-Abl cells treated with 2 µM STI-571 or 0.02 % DMSO as a vehicle control.  Whole 
cell extracts were prepared from cells harvested at 0, 2, and 8 hours after treatment, separated by 
SDS-PAGE (15 µg/lane) and transferred to nitrocellulose membranes.  Membranes were probed 
in sequence with antibodies directed against phospho-tyrosine, p21 and β-actin.  B) Northern 
blot analysis of p21 mRNA expression.  32Dcl3 v-Abl cells (t = 0) treated with 2 µM STI-571 or 
0.02 % DMSO for two hours (t = 2) as in A) were exposed to 10 mg/mL Actinomycin-D.  Total 
RNA was extracted from cell at the indicated time points and subjected to northern blot analysis 
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 with a 32P-labeled murine p21 cDNA probe.  Ethidium bromide stained 28S RNA is provided to 
demonstrate equal loading.  C)  Densitometric analysis of panels in B) with p21 signals 
normalized to 28S RNA density are plotted.  p21 mRNA half-life is tabulated (hours). 
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3.4. Discussion 
 
IL-3 is an important regulator of myeloid progenitor cell development.  In several organ 
systems, differentiation and development require changes in gene expression that are regulated at 
the posttranscriptional level by RNA binding proteins.  However, the role of posttranscriptional 
regulation in myeloid development, and particularly posttranscriptional effects mediated by 
cytokines such as IL-3, are poorly understood.  We used the IL-3 dependent myeloid progenitor 
cell line 32Dcl3 to test the hypothesis that IL-3 controls p21 expression during differentiation 
through posttranscriptional stabilization of its mRNA.  Here we have demonstrated that IL-3 has 
no effect on p21 protein stabilization, but rather operates to stabilize p21 mRNA in 32Dcl3 cells 
(Figures 8 and 9).  This effect required p21 3’UTR sequences.  The decrease in levels of p21 as 
32Dcl3 cells differentiated was shown to result from the faster turnover of p21 message in G-
CSF than in IL-3.  Our data also indicates that p21 mRNA stability downstream of IL-3 receptor 
activation is independent of ERK and PI3-kinase pathway activation (Figures 10 and 11).  
Several proteins have previously been reported to interact with the p21 3’UTR.  Using 32Dcl3 
protein extracts, we established that p21 RNA:protein complexes occur in vitro, identifying a 90 
kDa nuclear protein that binds the p21 3’UTR independently of IL-3 or G-CSF signaling.  In 
UV-crosslinking assays we demonstrate that distinct cytoplasmic p21 RNA:protein interactions 
occur within the proximal ARE region of the p21 3’UTR in response to either IL-3 or G-CSF.  
Association of a ~60-65 kDa protein with the p21 ARE region correlated with IL-3 mediated p21 
mRNA stabilization, whereas binding by a ~40-42 kDa protein correlated with destabilization of 
p21 transcripts in 32Dcl3 cells undergoing G-CSF-induced differentiation.  These findings are 
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 significant because they provide the first evidence for IL-3-mediated stabilization of mRNA 
transcripts in myeloid progenitor cells. 
Our data maps the IL-3 responsive domain of the p21 message to untranslated regions of 
the p21 transcript.  When only the coding region of p21 was transfected into 32Dcl3 cells, the 
stability of that transcript did not vary with IL-3 concentration upon Northern blot analysis (Fig 
12).  This was consistent with data from heterologous reporter assays that demonstrated that the 
p21 3’UTR sequences were required to increase reporter expression in response to stimuli that 
stabilize p21 transcripts191-193.  These effects were localized to nucleotides between 570-830 in 
the human 3’UTR 192,193; a region containing three AREs which is homologous to the murine 
580-883 sequence used in our UV-crosslinking assays.  For each cytokine tested in 32Dcl3 cells, 
UV crosslinking data showed that patterns of RNA:protein complexes were conserved between 
the full length 3’ untranslated region of p21 3’FL and truncated transcripts consisting of the 303 
proximal base pairs of the p21 3’ UTR (nucleotides 580-883, i.e., the p21 3’ 883 riboprobe) (Fig 
15).  This indicates that RNA:protein complex formation resulting from the use of the p21 3’883 
riboprobe was not an artifact of abnormal secondary structure arising from truncation of the full 
length 3’UTR, underscoring the utility of this riboprobe.  The change in RNA:protein complex 
formation noted in our UV crosslinking assay suggests a binary model where on- and off- 
binding to the proximal p21 3’UTR region by two specific RNA-binding proteins follows an IL-
3 to G-CSF switch.    
IL-3 has previously been shown to increase the mRNA stability of its receptor subunits, the 
IL-3 receptor α chain and the β common subunit, in mature human eosinophils256. High levels of 
the IL-3 receptor α chain are found in subsets of AML and correlate with poor prognosis22,248.  
Since IL-3 is often secreted by myeloid leukemia cells280,281, it is possible that high levels of the 
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 IL-3 receptor α chain are maintained in an autocrine fashion by IL-3 in leukemic myeloblasts.  
Although the β common subunit lacks AREs in its mRNA sequence, the human IL-3 receptor α 
chain contains one AUUUA motif in its 5’UTR.  The study by Wang et al. did not explore a 
mechanism for stabilization of IL-3 receptor mRNA by IL-3256. 
Our data suggests that IL-3 accomplishes mRNA stabilization by targeting specific RNA-
binding proteins to the p21 3’UTR.  A similar mechanism may be responsible for stabilization of 
IL-3 receptor α chain mRNA in normal and leukemic cells.  Since IL-3 is necessary to prevent 
differentiation of 32Dcl3 cells, it may be that IL-3 directs stabilizing RNA-binding proteins to a 
set of transcripts (including p21) that function to inhibit differentiation in IL-3 responsive 
myeloid progenitor cells or in IL-3 responsive leukemic myeloblasts. 
Posttranscriptional stabilization of p21 has been studied in animal and cell line models of 
muscle differentiation.  p21 is an important regulator of survival and differentiation in skeletal 
muscle, with peak levels of p21 protein found in terminally differentiated cells96,105,111,118.  
Increases in p21 expression during differentiation of C2C12 myogenic progenitor cells are 
associated with a 6-fold increase in p21 mRNA stability196.  In contrast to muscle, p21 
expression decreases as 32Dcl3 cells undergo granulocytic differentiation (Fig 8A).  This 
decrease in p21 protein levels is associated with a 3.5-fold decrease in p21 mRNA stability (Fig 
9A & B).  In myeloid cells, as in muscle, p21 protein expression appears to be a function of 
changes in mRNA stability, although the direction of change is opposite in the two cell types. 
Our data suggests that HuR is not a cytokine responsive p21 mRNA stabilizing protein.  
Exposure of 32Dcl3 cells to G-CSF, or the readdition of IL-3, had no effect on either HuR 
abundance or intracellular distribution in 32Dcl3 cells (Fig 16).  HuR was exclusively localized 
to the nucleus and undetectable in the cytoplasm, suggesting that compartmental redistribution of 
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 HuR may not be regulated by differentiation signals in 32Dcl3 cells.  This is important because 
cytoplasmic localization of HuR is associated with its ability to stabilize mRNAs293,294.  HuR has 
been shown to promote p21 mRNA stability in muscle through binding of AREs in the p21 
3’UTR196.  Analysis of cytoplasmic extracts from differentiating myoblasts by UV crosslinking 
identified HuR as a 37 kDa protein whose p21 ARE-binding activity was differentiation-
induced196.  This effect was correlated with cytoplasmic accumulation of HuR that was triggered 
by the myogenic differentiation stimulus. 
HuR independent stabilization of p21 mRNA has also been described and occurs in 
response to EGF or phenylephrine.  Although HuR binding to the p21 ARE region was 
demonstrated in MDA-468 breast cancer cells, it did not mediate EGF-induced p21 mRNA 
stabilization in this system, suggesting that additional RNA-binding proteins can regulate p21 
stability even in the presence of HuR binding193.  In addition, the α1 adrenergic agonist 
phenylephrine promoted p21 mRNA stability independent of HuR in the hepatoma cell line 
HepG2191.  Interestingly, phenylephrine induced the binding of two proteins of 24 and 52 kDa 
apparent mass to a 78 nucleotide riboprobe encompassing the conserved p21 AREs (bp 648-
726).  In both studies, the proteins responsible for p21 RNA stabilization were not identified. 
Our data indicates that binding of a 60-65 kDa protein, or prevention of the binding of a 40-
42 kDa protein, to the p21 3’UTR is a cytokine regulated phenomenon associated with p21 
mRNA stability.  UV-crosslinking assays demonstrated a cytoplasmic 60-65 kDa protein only 
from 32Dcl3 cells in IL-3 bound to both p21 3’FL and p21 3’883 riboprobes (Fig. 15)  In light of 
this, we examined the expression profile of hnRNP K, a 66 kDa protein that has been 
demonstrated to bind the p21 3’UTR and inhibit p21 translation.  We found that hnRNP K was 
detectable solely in the nuclear compartment in 32Dcl3 cells, with expression levels independent 
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 of the type of cytokine stimulus(Fig. 16).  Other p21 RNA-binding proteins with masses in the 
60-65 kDa range have not been described.  Due to the high sensitivity of UV crosslinking assays, 
hnRNP K cannot be ruled out as a candidate for our 60-65 kDa protein based solely upon 
subcellular localization analysis.  Since hnRNP K has been shown to inhibit p21 translation it is 
unlikely that hnRNP K:p21 mRNA interactions would lead to increased p21 protein expression 
levels.  Therefore, we speculate that the observed 60-65 kDa protein represents a novel IL-3 
regulated p21 3’UTR interacting protein that may act to stabilize p21 transcripts. 
Destabilization of p21 mRNA was correlated with binding of the 40-42 kDa protein to the 
p21 3’UTR.  Data from UV-crosslinking assays indicates that a cytoplasmic 40-42 kDa protein is 
activated to bind the p21 3’UTR when 32Dcl3 cells are switched out of IL-3 and induced to 
differentiate with G-CSF (Fig 15).  This coincides with the disappearance of the 60-65 kDa 
interacting protein.  AUF1, an RNA-binding protein that promotes mRNA decay, has been 
demonstrated to bind and destabilize p21 mRNA in competition with HuR184.  AUF1 expression 
is characterized by four splice variants, p37, p40, p42 and p45, all of which are capable of 
binding mRNA through their RNA recognition motifs (RRMs)295,296.  Most abundant in the 
nucleus, steady-state levels of these isoforms can also be found in the cytoplasm depending upon 
the cell type examined296.  Western blot analysis demonstrated multiple AUF1 isoforms present 
in 32Dcl3 nuclear extracts in cells propagating in IL-3 or undergoing differentiation in G-
CSF(Fig. 16).  AUF1 was also present in the cytoplasm, but with a restricted isoform 
distribution.  The apparent mass of the cytoplasmic signal is consistent with the presence of the 
40 and/or 42 kDa isoforms.  In THP-1 monocytic leukemia cells, induction of monocytic 
differentiation with TPA triggers dephosphorylation of the AUF1 p40 isoform, although the 
signal pathway mediating this effect was not established.  Dephosphorylation precipitated 
110 
 changes in its RNA binding affinity and correlated with stabilization of ARE-containing 
transcripts in these cells.  Interestingly, TPA did not induce a shift in the compartmental 
distribution of any AUF1 isoforms; the p37 and p40 isoforms were expressed in the cytoplasm, 
and the p42 and p45 isoforms expressed in the nucleus.  This is important because it indicates 
that posttranslational modification of AUF1 regulates its RNA binding activity and the half-life 
of its targets without stimulating shifts in localization during differentiation of myeloid cells.  
Thus, it is reasonable to speculate that posttranslational tuning of AUF1 binding affinity is 
sufficient to regulate p21 mRNA decay in response to cytokine signaling during granulocytic 
differentiation.  Ongoing investigations seek to determine if the 40-42 kDa p21 mRNA binding 
protein is AUF1. 
Deletion of the RNA-binding protein NF90 causes perinatal lethality in mice due to skeletal 
muscle defects that lead to respiratory failure194.  NF90, and its splice variant NF110 (90 and 110 
kDa, respectively), are predominantly nuclear proteins that function in RNA processing, mRNA 
export and localization, and initiation of translation297.  Shi et al. demonstrated that p21 mRNA 
and protein expression were dramatically reduced, along with the myogenic regulators MyoD 
and Myogenin, in skeletal muscle from NF90-/- animals194.  Specific NF90 binding to nucleotides 
511-883 in the p21 3’UTR was demonstrated by northwestern blot analysis using murine tissue 
extracts and recombinant NF90.  Our northwestern blotting data demonstrates a 90 kDa nuclear 
protein in 32Dcl3 cells that is capable of binding the p21 3’UTR (Fig 14).  Given the importance 
of NF90 to myogenic differentiation and its ability to bind p21 3’UTR sequences, it is 
conceivable that the 90 kDa protein we have detected is NF90.  We have confirmed that NF90, 
and its isoform NF110, are expressed in 32Dcl3 cells (Fig 16).  Both isoforms are localized to 
the nucleus and do not experience intracellular shifts to the cytoplasm during G-CSF induced 
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 differentiation.  NF90 may stabilize p21 primary transcripts in the nucleus and/or facilitate their 
export to the cytoplasm during myogenesis.  It is possible that NF90 binding is a required step 
for maintenance of primary p21 transcripts in the nucleus of 32Dcl3 cells. 
 
Because discreet signal transduction pathways have been linked with IL3 signaling, we 
have undertaken a preliminary characterization of which IL3 signaling pathway could be 
involved in the stabilization of p21 message.  IL-3 has been reported to activate the ERK and 
PI3-kinase pathways265,290.  Moreover, The ERK and PI3-kinase signaling pathways have been 
implicated in the induction and maintenance of p21 expression in hematopoietic cells285,298.  Our 
data indicates that IL-3 can induce ERK and Akt phosphorylation, markers of ERK and PI3-
kinase pathway activation respectively, when administered following exposure of 32Dcl3 cells to 
G-CSF (Fig 10A and 11A).  However, neither of these pathways is required for IL-3-mediated 
stabilization of p21 mRNA in our model system (Fig 10C and 11C).  This contrasts with p21 
mRNA stabilization induced by PGA2 in H1299 lung carcinoma cells, where stabilization 
required ERK-induced HuR binding to the p21 3’UTR.  Since PI3-kinase pathway activation by 
IL-3 was required for increased p21 expression in macrophages, it is possible that IL-3 promotes 
p21 expression via distinct mechanisms in mature and immature myeloid cells in response to 
PI3-kinase activity285.  IL-3 receptor ligation can also activate JAK2 and c-Src family tyrosine 
kinases, as well as the stress pathway kinases p38MAPK and JNK252,253.  Given these findings, 
further examination of IL-3 activated tyrosine or stress kinase signal transduction pathways, and 
their role in p21 mRNA stabilization in 32Dcl3 cells, is warranted. 
We have previously observed that p21 expression is elevated in 32Dcl3 cells transformed 
with the v-Abl oncogene95.  Since these cells do not depend upon IL-3 for survival, they 
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 provided a good model to determine if v-Abl activity was simply replacing IL-3 signal pathways 
to stabilize p21 mRNA.  Our data did not support this mechanism.  Inhibition of v-Abl kinase 
activity with STI-571 revealed a decrease in p21 protein levels, but demonstrated no change in 
p21 mRNA stability.  p21 protein stability was also unaffected by v-Abl inhibition (data not 
shown) suggesting that v-Abl activity may act at the level of transcription or translation.  Recent 
work has demonstrated that BCR-ABL promotes leukemic transformation in myeloid cells 
through translational inhibition of C/EBPα and translational activation of MDM2299,300.  These 
effects are mediated by BCR-ABL-dependent upregulation of several RNA binding proteins 
which specifically bind C/EBPα and MDM2 mRNA transcripts.  We have demonstrated that a 
distinct 46-48 kDa protein in 32Dcl3 v-Abl cells interacts with the p21 3’FL and p21 3’883 
riboprobes.  Translational upregulation of p21 by specific RNA-binding proteins may contribute 
to differentiation blockade and/or to v-Abl induced leukemogenesis.  Further analysis of p21 
expression in 32Dcl3 v-Abl cells will focus on mechanisms that regulate translation and 
identification of p21 RNA-binding proteins that may impact this process. 
In conclusion, the findings presented here suggest that high levels of p21 protein in 
proliferating 32Dcl3 myeloid progenitor cells results from IL-3-mediated stabilization of p21 
mRNA.  This work provides the first evidence for IL-3-mediated stabilization of mRNA 
transcripts in myeloid progenitor cells and may represent a mechanism that contributes to 
leukemic phenotypes in IL-3 secreting myeloblasts or those overexpressing the IL-3 receptor α 
chain.  Future investigations will focus on characterization of p21 RNA-binding proteins and the 
signal pathways which regulate their binding activity.  
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 4.1. Introduction 
 
 Neutrophil differentiation is a 7 to 10 day process that is often divided into stages based 
upon cell morphology and the expression of distinct cytoplasmic granules.  Granule constituents 
are proteins that are responsible for the inflammatory and microbicidal effects initiated by 
neutrophils as part of the innate immune response.  As neutrophil differentiation proceeds, 
granule proteins accumulate first in primary azurophilic granules, then secondary and tertiary, or 
“specific,” granules.  These granules comprise vesicles that sequester granule proteins to prevent 
their premature activation and are identified based upon their affinity for specific dyes.  The 
protein complement within a particular granule is thought to be regulated through synchronized 
expression of genes at the level of transcription rather than by a specific protein sorting 
mechanism that varies during differentiation301,302.  Although the specific transcription factors 
that activate granule protein gene expression have been well characterized6,301, the mechanisms 
that regulate the timing of gene expression during differentiation are not well understood. 
 Changes in p21 levels have been linked to differentiation in several cell types including 
epidermal, bone forming and hematopoietic cells.  In support of an inhibitory role for p21 during 
differentiation, our laboratory has shown that p21 expression is highest in myeloblasts and then 
dramatically decreased in post-mitotic granulocytes in both normal cell lines and cord blood 
derived stem cells differentiated in vitro99,100.  This supports the finding of high p21 levels in 
undifferentiated myeloblasts isolated from patients with chemoresistant AML3.  There had been 
one report, in primary keratinocytes, of differentiation blockade mediated by p21.  In 
keratinocytes exposed to differentiation inducers, ectopic p21 inhibited the expression of genes 
normally found in terminally differentiated cells and prevented morphologic maturation109.  
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 More recent work has indicated that p21 delays osteoblast differentiation kinetics303.  The effect 
of p21 upon expression of genes associated with granulocytic differentiation has been 
unexplored. 
 IL-3 is required for maintenance of an undifferentiated state in 32Dcl3 cells.  In Chapter 
3, we demonstrated that IL-3 can stabilize p21 mRNA, contributing to the high levels of p21 
protein expression found in these myeloid progenitor cells.  Since p21 expression decreases with 
the onset of differentiation (Fig. 4 and Fig. 8), we hypothesized that p21 is a downstream effector 
of IL-3-mediated differentiation blockade in 32Dcl3 cells.  To address this hypothesis we utilized 
short interfering RNAs (siRNAs) to specifically downmodulate p21 in 32Dcl3 cells.  We 
demonstrate here that loss of p21 is sufficient to induce the premature expression of primary 
granule proteins in myeloblasts and accelerates G-CSF induced granulocytic differentiation. 
 
4.2. Materials and Methods 
 
4.2.1. Cells and Culture 
   – see section 2.3.1 
4.2.2. Differentiation 
   – see section 2.3.2 
4.2.3. Plasmids 
 Retroviral constructs were based on the MIG plasmid (a kind gift of Luk Van Parijs, 
Massachusetts Institute of Technology), which contains an IRES-GFP cassette downstream of its 
multiple cloning region.  Using standard methods, the Gateway® vector conversion cassette 
(Invitrogen, Carlsbad, CA), reading frame B, was blunt-end cloned into the MIG Hpa I site and 
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 transformed into DB3.1 cells (Invitrogen) to create a Gateway® destination vector, MIGccd.  
Human p21 wild-type cDNA (accession# NM_078467) carrying a myc-his tag was PCR 
amplified and cloned into the pENTR-D-TOPO (Invitrogen) plasmid to create a Gateway® entry 
vector, pENTR-D hp21WT.  The expression clone MIG hp21WT was synthesized by combining 
pENTR-D hp21WT and MIGccd in an LR clonase recombination reaction (Invitrogen) per 
manufacturer’s instructions.   
 The pSilencer 2.1-U6 Hygro expression vector (Ambion, Austin, TX) was utilized to 
deliver hairpin siRNA targeting murine p21.  Complementary oligonucleotides based upon 
nucleotides 140-162 (Genbank Accession # NM_007669) of the murine p21 transcript (Primer A 
-  
GATCCGCAAAGTGTGCCGTTGTCTCTTCCTGTCAAGACAACGGCACACTTTGCTTTTT
CGGCCGGAA; Primer B – 
AGCTTTCCGGCCGAAAAAGCAAAGTGTGCCGTTGTCTTGACAGGAAGAGACAACGG
CACACTTTGCG) were annealed and cloned into the BamHI and HindIII sites of pSilencer 2.1-
U6 Hygro to generate pSilencer mp21si.  pSilencer 2.1-U6 Hygro was used to deliver negative 
control siRNA (agcttttccaaaaaactaccgttgttataggtgtctcttgaacacctataacaacggtagtggatccc).  
Retroviral siRNA expression vectors were synthesized by cloning siRNA cassettes from the 
above pSilencer plasmids, which consisted of the U6 promoter and hairpin sequences, by blunt-
end cloning of PCR amplicons (forward primer – caccgaggagaagcatgaattcc, reverse primer – 
cgttgtaaaacgacggccag) into the HpaI site of MIG to generate MIG mp21si and MIG CTLsi.  All 
plasmids were verified by sequencing analysis.  
 
4.2.4. siRNA Transfection and Stable cell lines 
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  32Dcl3 cells were transfected with pSilencer siRNA plasmids (Ambion, Austin, TX) by 
electroporation (1.5x107 cells in Opti-Mem I (Invitrogen, Carlsbad, CA), 10 µg plasmid DNA, 
960 uF, 280 V, 0.4 cm gap), allowed to recover for 48 hours and selected with 1 mg/ml 
hygromycin (Calbiochem, La Jolla, CA) for 10 days in IL-3 supplemented RPMI as noted in 
section 2.3.1.  Survivors were cloned by limiting dilution and passaged thereafter with 500 ug/ml 
hygromycin. 
 
4.2.5. Retroviral Transduction 
   – see section 2.3.5 
4.2.6. Western Blotting 
   –see section 3.3.3 
4.2.7. Northern Blotting 
   – see section 2.3.7 
 
4.3. Results 
 
 We have previously demonstrated that 32Dcl3 cells are a good model system for studying 
the initiation of granulocytic differentiation (Fig 8A).  To determine if p21 expression patterns 
were inversely correlated with those of differentiation-specific genes, we established the 
temporal expression patterns of p21 and the primary granule proteins myeloperoxidase (MPO) 
and proteinase-3 (PR-3) in 32Dcl3 treated with G-CSF for 13 days.  Western blot analysis 
demonstrated that p21 levels decrease by >75% within 48 hours of the switch from IL-3 to G-
CSF and remained low in terminally differentiated cells at day 13 (Fig 18).  In contrast, both 
MPO and PR-3 expression is induced to high levels within 48 hours of G-CSF stimulation.  
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 These proteins are synthesized as proenzymes which become processed into smaller forms 
during differentiation.  The high molecular weight form of PR-3 is maximal at 48 hours and 
diminishes thereafter, indicating that molecular processes associated with proper neutrophil 
maturation are intact in our experimental system.  Morphologic differentiation was confirmed by 
the presence of segmented neutrophils in Diff-Quik stained cytospins (data not shown).  
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Figure 18. Primary granule protein expression is inversely correlated with that of p21 in 32Dcl3 cells. 
32Dcl3 cells propagating in 1 ng/mL IL-3 were washed and stimulated to differentiate with 100 
ng/mL G-CSF.  Each lane contains 3x105 viable cells that were harvested daily and boiled 
directly in laemmli buffer.  Samples were subjected to SDS-PAGE and immunoblot analysis 
with p21, myeloperoxidase (MPO) and proteinase-3 (PR3) antibodies.  β-actin is provided as a 
loading control.   
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  We next sought to address the effect of reducing physiological levels of p21 on 32Dcl3 
cell differentiation.  To knock down p21 expression, we generated stable sublines of 32Dcl3 cells 
expressing U6 promoter driven hairpin siRNA targeting murine p21 and sublines expressing 
negative control siRNA.  To facilitate targeting of dsRNA to the cytoplasm, where RNA 
interference primarily occurs, the human mir-23 microRNA loop motif (CTTCCTGTCA) was 
incorporated into the hairpin sequence.  p21 protein knockdown was >95% in both polyclonal 
and clonal cell lines compared to control cells (Fig. 19).  Northern blot analysis of polyclonal 
cells demonstrated a comparable decrease in p21 mRNA expression (Fig. 20B, IL-3 lanes). 
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Figure 19. siRNA mediated knockdown of p21 in 32Dcl3 cells. 
A)  Western blot analysis of 32Dcl3 stable transfectants harboring control siRNA (CTL) or 
murine p21 siRNA.  Polyclonal (PC) and clonal murine p21 siRNA cell lines (#) are indicated.  
Whole cell protein extracts were separated by SDS-PAGE, transferred to nitrocellulose and 
immunoblotted in sequence with antibodies against p21 and β-actin (loading control). 
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  To determine if p21 knockdown altered the expression of differentiation specific genes, 
polyclonal cells expressing control or p21 siRNA were treated with G-CSF for 3 days and MPO 
expression was examined.  As in the parental 32Dcl3 cells, MPO protein expression in control 
siRNA cells increased dramatically after 48 hours, correlating with a steep decrease in p21 
expression (Fig 20A).  In cells expressing p21 siRNA, MPO protein expression was high in cells 
propagating in IL-3 and accelerated in response to the G-CSF stimulus.  By comparison MPO 
mRNA expression was low both in control and p21 siRNA expressing cells, rising only after the 
initiation of differentiation (Fig 20B).  Because premature upregulation of MPO protein is not 
accompanied by an increase in mRNA, this indicates that the high level of MPO protein in p21 
siRNA cells does not result from transcriptional upregulation or from increased stability of 
mRNA.  The p21 siRNA is augmenting MPO protein formation or slowing MPO protein decay, 
suggesting that p21 inhibits MPO translation or MPO protein stability in 32Dcl3 cells. 
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Figure 20.  Loss of p21 triggers premature myeloperoxidase expression 
A)  Polyclonal 32D cells expressing control siRNA or murine p21 siRNA propagating in 1 
ng/mL IL-3 underwent a four hour cytokine starvation (Ø) and were stimulated to differentiate 
with 100 ng/mL G-CSF.  Whole cell protein extracts were prepared from cells harvested daily, 
separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted in sequence with p21, 
myeloperoxidase (MPO) and β-Actin antibodies (loading control).  b)  Northern blot analysis of 
total RNA harvested from cells in A) at the indicated time points were subjected to northern blot 
analysis with 32P-labeled p21, MPO and GAPDH (loading control) cDNA probes.   
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  To validate these findings we utilized an independent retroviral siRNA delivery system.  
32Dcl3 cells were transduced with retroviruses carrying control siRNA or p21 siRNA and sorted 
on the basis of GFP expression.  Polyclonal and clonal sublines were established and analyzed 
for p21 protein expression by western blotting (Fig. 21A).  p21 expression was reduced in excess 
of 80% in two clonal cell lines expressing p21 siRNA compared to control siRNA or parental 
cell lines.  Whereas MPO protein expression is minimal in controls, expression is markedly 
upregulated in p21 siRNA cell lines in the absence of a differentiation stimulus.  This data 
recapitulates the findings derived with plasmid delivered siRNA and reinforces the observation 
that p21 downmodulation is sufficient to increase primary granule protein expression in 32Dcl3 
cells.   
Because this data indicated an inhibitory effect of p21 on expression of differentiation-
associated granule proteins, we hypothesized that p21 might slow myeloid differentiation.  We 
therefore examined cell morphology to determine if p21 knockdown altered the kinetics of 
32Dcl3 morphological differentiation.  Because 32Dcl3 cells take 10-14 days to differentiate into 
neutrophils, we examined myeloblasts exposed to control or to p21 siRNA after just 4 days of G-
CSF treatment.   Following exposure to G-CSF at 30 ng/ml for 4 days, segmented neutrophils are 
apparent in 32Dcl3 sublines expressing p21 siRNA, but absent in controls, suggesting that 
knockdown of endogenous p21 accelerates granulocytic differentiation (Fig. 21B). 
 We next sought to determine if premature MPO upregulation in p21 siRNA expressing 
cells could be suppressed by introduction of a siRNA insensitive p21 transgene.  32Dcl3 cells 
carrying the p21 siRNA that inhibited endogenous murine p21 were transduced with a control 
retrovirus or retrovirus expressing a human p21 cDNA that was resistant to the murine p21 
siRNA (data not shown).  Polyclonal and clonal “rescue” sublines were established and 
123 
 examined for human p21 transgene expression by western blotting (Fig 21C).  Two rescue 
sublines, 1 and 4, exhibited levels of human p21 transgene expression comparable to those found 
in parental 32Dcl3 cells.  MPO and PR-3 protein expression was suppressed in these clones 
when compared to the siRNA cells transduced with control virus.  This confirmed that the 
increased MPO in p21-knockdown clones could be rescued by exogenous human p21 and that 
modulation of MPO levels is a direct effect of p21 and not a nonspecific effect of siRNA.  
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Figure 21.     Rescue of p21 siRNA with exogenous human p21 suppresses premature granule protein 
expression.  
A)  Retroviral siRNA reduces endogenous p21 protein in 32Dcl3 cells.  Parental 32Dcl3 cells 
(32D) were transduced with retroviruses containing control siRNA (CTL) or p21 siRNA (two 
representative clones depicted).  Whole cell protein extracts were immunoblotted in sequence 
with antibodies against p21, myeloperoxidase (MPO) and β-actin (loading control).  B)  Loss of 
p21 accelerates granulocytic differentiation.  32Dcl3 cells from A) were washed and treated with 
30 ng/mL G-CSF for 4 days.  Cytospins of harvested cells were prepared with Diff-Quik stain.   
C)  Rescue of p21 restores myeloperoxidase suppression.  32Dcl3 cells expressing stable plasmid 
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 96p21 siRNA were transduced with either a control virus or one carrying siRNA resistant human 
p21 and maintained in 1 ng/mL IL-3.  Polyclonal (PC) and two clonal cell lines were derived by 
cell sorting based on GFP expression.  Protein extracts were immunoblotted in sequence with 
antibodies targeting p21, myeloperoxidase (MPO), proteinase-3 (PR-3) and β-actin. 
126 
  
4.4. Discussion 
 
 Defining the molecular mechanisms that prevent myeloid progenitor cells from maturing 
is important because defects in maturation contribute to the development of myeloproliferative 
and myelodysplastic diseases, including AML.  IL-3 is an important developmental factor for 
myeloid progenitor cells and is required to maintain the undifferentiated state in 32Dcl3 cells.  
The mechanisms employed by IL-3 to block differentiation are not well understood.  Since IL-3 
maintains high levels of p21 in 32Dcl3 cells, we tested the hypothesis that p21 is an inhibitor of 
myeloid differentiation.  Here we have demonstrated that siRNA knockdown of p21 is correlated 
with premature expression of the primary granule proteins MPO and PR-3, proteins not abundant 
in cells maintained as myeloblasts by IL-3.  Rescue with human p21 in these cells suppressed 
this early expression.  These findings indicate that p21 may contribute to maintenance of the 
myeloblast phenotype and may regulate the tightly controlled expression of primary granule 
proteins.  p21 knockdown was also found to accelerate morphologic granulocytic differentiation 
in 32Dcl3 cells stimulated with G-CSF, indicating that p21 may antagonize differentiation at an 
early regulatory point and not simply cause primary granule protein suppression. 
 Our data demonstrates that knockdown of p21 expression is sufficient to cause an 
increase in MPO and PR-3 expression in 32Dcl3 cells.  Moreover, the concurrent effect of p21 
on two primary granule proteins suggests that this is a coordinated pathway.  In support of this, 
rescue of the siRNA phenotype with exogenous human p21 was evident for both MPO and PR-3.  
However, it is possible that the demonstrated upregulation of MPO and PR-3 was an artifact of 
clonal selection.  This is unlikely because premature expression occurred in both polyclonal and 
clonal sublines, and was observed using two independent platforms of p21 siRNA delivery.  At 
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 this point we do not know if p21 effects on granule protein expression arise from direct or 
indirect p21 binding to RNA transcripts or as a downstream manifestation of other p21 functions.   
 MPO protein upregulation was not accompanied by an increase in mRNA, implying that 
p21 regulation of MPO occurs at a posttranscriptional level in 32Dcl3 cells.  Our data suggests 
that p21 inhibits MPO translation and/or promotes MPO decay.  Although MPO mRNA 
synthesis is transient, occurring primarily at the promyelocytic stage, MPO protein is long-lived 
and abundant in terminally differentiated neutrophils301.  This occurs because, once synthesized, 
MPO is stored in granules until they are exocytosed and therefore protected from degradation304.  
On this basis, we speculate that it is more likely p21 is regulating MPO translation.  Analysis of 
MPO half-life in our system would help to clarify whether MPO degradation is a function of p21 
levels.   
 Translational repression has been identified as an important mechanism mediating 
differentiation blockade in leukemic cells305.  Activation of the RNA-binding proteins hnRNP E2 
and calreticulin by leukemic fusion proteins has been demonstrated to suppress translation of the 
critical myeloid developmental factor C/EBPα in primary AML cells300,306.  Since IL-3 can 
induce calreticulin expression in myeloid cells307, it is possible that calreticulin is activated as a 
translational repressor by IL-3 in a fashion similar to its recruitment by leukemogenic signaling 
pathways.  Interestingly, calreticulin acts as a molecular chaperone during MPO biosynthesis in 
the endoplasmic reticulum, facilitating the insertion of a critical heme group into the MPO 
proenzyme308.  Although interactions with p21 have not been reported, it is reasonable to 
speculate that p21 acts downstream of IL-3 to engage calreticulin as a translational repressor of 
primary granule proteins such as MPO. 
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  Our data demonstrates that downmodulation of p21 with siRNA accelerates 
differentiation in 32Dcl3 cells.  This data is consistent with findings of accelerated osteoblast 
differentiation in cells derived from p21-/- mice, and p21 inhibition of keratinocyte 
differentiation109,303.  Moreover, our data suggests that the high levels of p21 found in subsets of 
AML patients may contribute to pathogenesis in part by antagonizing differentiation3.  However, 
peripheral white blood cell counts in p21-/- mice are normal, suggesting that the absence of p21 
does not result in accelerated neutrophil differentiation in an animal model.  This may be due to 
compensation by other cip/kip family proteins, which has been demonstrated to occur in muscle 
through analysis of p21/p57 double knockout animals3.  Since siRNA strategies induce a somatic 
loss of gene expression, interpretation of data is not confounded by compensatory mechanisms 
that may occur in the germline or at the tissue level.  Future investigations using siRNA-
mediated knockdown of p21 in human myeloid progenitor cells or conditional p21 knockouts in 
animal models will be needed to more fully determine the role of p21 in normal myeloid 
differentiation. 
In conclusion, our investigation in differentiating myeloid cells revealed that siRNA-
mediated knockdown of p21 accelerated the kinetics of G-CSF induced differentiation. This 
effect was associated with premature expression of primary granule proteins due to mechanisms 
operating at the posttranscriptional level.  Since high levels of p21 have been described in 
subsets of AML, our finding of accelerated differentiation in p21 knockdown cells suggests that 
differentiation blockade by p21 may be one mechanism that contributes to AML pathogenesis. 
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 5. Chapter V 
 
5.1. Discussion and Future Directions 
 Prior work has delineated changes in the level of expression of the multi-functional 
adaptor protein p21 during myeloid differentiation.  However, the functional role of p21 in 
differentiating myeloid cells (particularly during granulopoiesis) has not hitherto been examined, 
nor have mechanisms of its regulation been fully elucidated. 
 Studies in chapter 2 demonstrated that p21 was an important regulator of survival during 
granulocytic differentiation.  Evidence published elsewhere supported an anti-apoptotic role for 
p21 in myeloid cells undergoing monocytic differentiation.  Therefore, the hypothesis that p21 
inhibits apoptosis during granulocytic differentiation was explored.  Contrary to expectations, 
exogenous expression of p21 had a proapoptotic effect in 32Dcl3 cells during the myeloblast to 
granulocyte transition.  This finding was consistent with our overall hypothesis that p21 is an 
inhibitor of differentiation insofar as p21 downmodulation was required for cells to survive to 
maturity.  A proapoptotic role for p21 during the myeloblast to myelocyte transition is also 
significant because it suggests that p21 function in cell survival is distinct and opposite between 
granulocytes and monocytes.  Our finding groups granulocytes with several other cell types in 
which p21 has been noted to promote cell death rather than survival 56.  Of note, cells cultured in 
high levels of IL-3 were resistant to p21-promoted apoptosis that was manifested when cells 
were cultured in low IL-3 concentrations or in G-CSF.   The ability of cells cultured in high 
levels of IL-3 to resist an apoptotic function of p21 could have several causes.  One potential 
mechanism is that post-translational modifications of p21 stimulated by IL-3 were operating to 
minimize its apoptotic potential.  Alternatively, differences in IL-3 and G-CSF survival signaling 
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 may account for the relative sensitivity to p21 proapoptotic effects.  Our results indicate that p21 
promotion of cell death can be a cytokine specific phenomenon that occurs in the absence of 
other death signals.  This may be a mechanism utilized to put a brake on myelopoiesis in 
response to acute changes in the cytokine environment. 
 Several methodological limitations should be noted.  This study was conducted using a 
murine cell line model of myeloid development.  Findings generated in cell line model systems 
do not always recapitulate in vivo physiology and may be phenomena that are cell line-, or 
species-specific.  Although the 32Dcl3 system has yielded many insights about myeloid 
development, validation of p21 proapoptotic effects in other cell lines, particularly of human 
origin, and in primary human cells is required.  Secondly, the process of generating polyclonal 
and clonal sublines overexpressing p21 may have resulted in adaptations that both 
accommodated the high levels of p21 and distorted the response to differentiation stimuli.  This 
potential problem could be addressed though synthesis of a control cell line overexpressing cdk-
inhibitors related to p21 such as p27.  Such a control would help to discriminate between 
possible cell cycle effects that may be promoting apoptosis and proapoptotic effects specific to 
p21.  We believe that p27 is not expected to recapitulate p21 antagonism of cell survival because 
p27 levels rise with 32Dcl3 differentiation in contrast to the observed fall in p21 expression (Fig 
4D)158.  Lastly, our series of experiments is subject to the usual concerns related to 
overexpression studies such as nonphysiologic sequestration of p21 binding partners, abnormal 
subcellular localization, or other effects that may aberrantly stress the 32Dcl3 cells when 
removed from IL-3 survival signals. 
 Candidate mechanisms through which p21 could promote apoptosis have yet to be 
delineated.  While our data demonstrated that p21 induced apoptosis was characterized by 
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 activation of the effector caspase caspase-3, this does not pin down a mechanism since multiple 
pathways associated with intrinsic and extrinsic apoptotic triggers can lead to caspase-3 
activation.  Future experimentation should establish which of these pathways is recruited by p21.   
Presumably such experiments will highlight a mechanism that differs between IL3 and G-CSF, 
since these cytokines are divergent in their sensitivity to p21-induced cell death.  Among the 
many questions raised by our findings are:  1) Is there a survival advantage for cells in G-CSF if 
p21 levels are dropped (e.g., by RNAi) below the basal level that remains after IL-3 withdrawal?  
2)  Is p21 protein modified by IL-3 such that its compartmentalization or binding partners change 
in a way to minimize p21’s proapoptotic potential?  3)  Would p21 mutants that lack cdk2-
binding activity remain capable of promoting apoptosis?  4)  Does IL-3 alter the expression or 
localization of p21 binding partners with a resultant change in p21 function?  Experimental 
approaches to dissect these possibilities include 2-D gel electrophoresis to screen for p21 
posttranslational changes, followed by mass spectroscopy and peptide sequencing.  Correlation 
of findings from 32Dcl3 cells, or human myeloid progenitors, with p21 posttranslational 
modifications that occur in p21 expressing leukemic cells would serve to identify residues with 
modifications that are specifically altered in leukemia. 
 Chapter 3 addressed how the cytokines IL-3 and G-CSF regulated p21 expression in 
myeloid progenitor cells.  We found that p21 expression was controlled at the level of mRNA 
stability rather than protein stability.  These findings are significant because they provide the first 
evidence for IL-3-mediated stabilization of mRNA transcripts in myeloid progenitor cells.    
Heretofore, gene expression regulated by IL-3 has been primarily attributed to changes in 
transcriptional activity 252.  Post-transcriptional regulation of mRNA transcripts in response to 
changes in cytokine signaling has been relatively unexplored in myelopoiesis.  Our data indicate 
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 that changes in cytokine signaling can produce changes in RNA:protein interactions.  This 
implies that cytokine-activated RNA-binding factors can coordinate gene expression at the post-
transcriptional level in myeloid progenitor cells.  Such a mechanism would facilitate rapid 
developmental responses to changes in the cytokine milieu within the marrow cavity, such as 
those occurring during emergency granulopoiesis following infection.  Cytokine-coordinated 
changes in mRNA stability also may be an important mechanism in leukemogenesis.     
Given the likely biological impact of cytokines acting on posttranscriptional targets, it is 
important to dissect the signaling mechanism that underlies this action.  The fact that IL-3 altered 
p21 stability even in the presence of actinomycin D indicates that no new gene transcription was 
necessary to alter the p21 transcript half-life.  The rapidity of the IL-3 effect is most compatible 
with a model in which IL-3 alters the phosphorylation status of a target RNA binding protein (yet 
to be confirmed) and enables it to bind (or alternatively to be released from) the p21 transcript.  
Such a model makes it worthwhile to explore IL-3 signaling pathways in order to determine 
which phosphorylation cascade could be responsible for this phenomenon.  The PI3-kinase 
pathway was of particular interest because a recent report had indicated that IL-3 increased p21 
levels in macrophages through a PI3-kinase-dependent mechanism285.  However, our data ruled 
out involvement of this pathway.  Similarly, the ERK pathway has been shown to promote high 
levels of p21 expression in AML cells and to stabilize p21 transcripts in response to PGA2 
treatment in colon carcinoma cell lines189,298.  Although activated by IL-3 in 32Dcl3 cells, the 
ERK pathway did not mediate p21 stabilization.  Several other signaling molecules can be 
activated by IL-3 including the p38MAPK and JNK stress kinases, JAK2 and members of the c-Src 
family of tyrosine kinases252,253.  Given these findings, further examination of IL-3 activated 
tyrosine or stress kinase signal transduction pathways, and their role in p21 mRNA stabilization 
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 in 32Dcl3 cells, is warranted.  It is also possible that multiple pathways can independently 
stabilize p21 mRNA downstream of IL-3 receptor ligation.  Such redundant stabilizing signals 
could be investigated by the simultaneous application of signal pathway inhibitors and may be 
informative should experiments targeting inhibition of isolated pathways be indeterminate.   
Interpretation of data in chapter 3 should be tempered by limitations of the methods and 
approach used.  As in chapter 2, all experiments were conducted using a cell line model and are 
subject to the same caveats previously noted.  Similar experiments should be conducted in 
human cell lines, or primary human stem cells differentiated in vitro, to validate our findings.  In 
addition, demonstration of RNA:protein interactions was dependent upon the use of in vitro 
binding assays.  The main caution with in vitro studies is that they have the inherent limitation of 
being conducted in the absence of intact cells, tissues or whole animals, where findings may not 
truly represent physiologic reality.  They remain, however, a suitable starting point to narrow the 
focus of subsequent in vivo studies.  An additional concern is that these assays employed in vitro 
transcribed riboprobes.  While riboprobe titration can be tightly controlled, riboprobe misfolding 
in experimental solutions may create artificial secondary structures, thereby confounding the 
interpretation of results. 
The nucleotide sequences that are responsible for IL-3-mediated stabilization of p21 mRNA 
have not been determined.  We have demonstrated that RNA-binding proteins from 32Dcl3 cells 
can interact with the p21 3’UTR in a cytokine-regulated manner.  Because we have not ruled out 
the importance of sequences downstream of the proximal 303 nucleotides, future studies should 
attempt to fine map IL-3 responsive elements using UV-crosslinking and RNA electrophoretic 
mobility shift (REMSA) assays.  Short sequences that are found to be regulated by IL-3 can be 
incorporated into heterologous reporter constructs and analyzed in vivo to verify IL-3 
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 responsiveness.  Plasmids containing luciferase reporter genes fused to p21 3’UTR sequences 
have been described195 and have been made available to our laboratory.  In addition, IL-3 
responsive elements could be utilized as baits to affinity purify cytokine responsive RNA-
binding proteins from differentiating cells.  Purified proteins would be identified by mass 
spectrometry with p21 RNA binding activity validated in vitro by REMSA supershift assays and 
in vivo utilizing IP-RT-PCR assays (i.e., a RNA “ChIP” assay).  REMSA supershift assays will 
also be used to determine if putative p21 binding proteins identified on the basis of molecular 
mass in UV-crosslinking assays, such as AUF1, are present in RNA-binding complexes. 
 Chapter 4 investigated the hypothesis that p21 is an effector of differentiation blockade 
downstream of IL-3 signals in myeloid progenitors.  Work from our laboratory, and published 
work of others, has previously demonstrated that IL-3 inhibits G-CSF-induced granulocytic 
differentiation in 32Dcl3 cells282,309.  In Chapter 3, we demonstrated that IL-3 maintains high 
levels of p21 expression, in part, through stabilization of its mRNA.  Results from experiments 
utilizing siRNA mediated suppression of p21 indicate that p21 may contribute to maintenance of 
the myeloblast phenotype and may regulate the tightly controlled expression of primary granule 
proteins.  The observed concurrent effect of p21 on two primary granule proteins suggests that 
this is a coordinated pathway.  Together, our findings support a model where p21 functions at the 
posttranscriptional level to inhibit translation of primary granule proteins.  p21 has not been 
reported to regulate protein translation; therefore, validation of such a model would define a 
novel function for p21.  Our data also indicated that p21 knockdown caused an acceleration of 
granulocytic differentiation in 32Dcl3 cells, suggesting that p21 may antagonize differentiation 
at an early regulatory point in addition to causing primary granule protein suppression.  Given 
the high expression levels of p21 reported in AML subsets, the physiologic role of p21 as an 
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 inhibitor of normal myelopoiesis may be a mechanism that is co-opted by leukemogenic signals 
to promote differentiation blockade.   
 Validation of the inhibitory effect p21 exerts upon myeloid differentiation and the 
potential mechanism through which p21 is operating requires further clarification.  Due to 
limitations of cell line experimental systems, future investigations using siRNA-mediated 
knockdown of p21 in primary human myeloid progenitor cells, or conditional p21 knockouts in 
animal models will be needed to more fully determine the role of p21 in normal myeloid 
differentiation.  Mechanistic studies would include determining whether suppression of primary 
granule proteins by p21 occurs due to translational inhibition or as a result of increased protein 
degradation.  To complement this approach, siRNA rescue experiments using p21 mutants would 
provide a functional mapping of p21 domains, and/or phosphorylation sites, required for primary 
granule protein suppression.  If posttranslational modification of p21 is implicated, a broader 
dissection of IL-3 activated signal pathways would then be pursued. 
 
5.2. Conclusion 
Previous work from our laboratory has characterized dynamic changes in p21 protein 
expression and subcellular compartmentalization during myelopoiesis, suggesting that p21 plays 
an important role in myeloid development.  The studies described in this thesis utilized the 
32Dcl3 myeloblast cell line model to explore the hypothesis that p21 is an inhibitor of 
granulocytic differentiation.  A model of our findings is presented in Figure 22.  In support of 
our hypothesis, the data herein demonstrates that 1) p21 antagonizes survival signals provided by 
G-CSF in differentiating cells, 2) p21 inhibits the expression of genes associated with early 
myeloid differentiation, and 3) that loss of p21 accelerates granulocytic differentiation.  We also 
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 demonstrate that p21 mRNA stability is dependent upon IL-3 signaling events, providing the first 
evidence for IL-3-mediated stabilization of mRNA transcripts in myeloid progenitor cells (Fig. 
23).  Because high levels of p21 have been described in subsets of AML, our findings suggest 
that differentiation blockade by p21 is one mechanism that contributes to AML pathogenesis. 
 
Survival
IL-3
p21
Differentiation
G-CSF
(Ch.2)
(Ch.3)
(Ch.4)
 
Figure 22.   Role of p21 in myelopoiesis. 
p21 antagonizes survival and primary granule protein expression during early myeloid 
differentiation.  IL-3 inactivates the proapoptotic effects of p21 and maintains high levels of p21 
in undifferentiated cells. 
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Figure 23.  Proposed model of p21 mRNA stabilization by IL-3. 
IL-3 activates signal pathways in 32Dcl3 cells (bold arrow) which promote stabilizing 
RNA:protein interactions in the p21 3’UTR leading to robust p21 protein expression.  Loss of 
IL-3 signaling (dashed arrows) causes destabilizing RNA:protein interactions, accelerates p21 
mRNA decay and results in decreased p21 protein expression.   
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